document incorporate reference specify portion registrant definitive proxy statement file commission pursuant regulation connection annual meeting incorporate reference iii report base closing price share exclude share registrant common stock hold executive officer director stockholder ownership exceed common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registrant gilead sciences inc annual report table content item business item property item legal proceeding item submission matter vote security holder ii item market registrant common stock relate stockholder matter item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure iii item director executive officer registrant item executive compensation item security ownership certain beneficial owner management item certain relationship relate transaction item control procedure iv item exhibit financial statement schedule report form k signature certification right trademark copyright trade name business include follow gilead gilead sciences hepsera leaf shield design leaf shield design bw liver design tablet design bw tablet design color viread vistide daunoxome ambisome tamiflu register trademark belong hoffmannla roche report include trademark service mark trade name company item business forwardlooke statement risk factor report include forwardlooke statement particular statement expectation belief plan objective assumption future event performance contain incorporate reference report base forwardlooke statement current expectation future event believe expectation reasonable forwardlooke statement inherently subject risk uncertainty control actual result differ materially suggest forwardlooke statement reason include discuss report head risk factor affect gilead give risk uncertainty caution place undue reliance forwardlooke statement forwardlooke statement include report date hereof undertake specifically decline obligation update statement publicly announce result revision statement reflect future event development report indicate refer gilead subsidiary overview gilead sciences inc biopharmaceutical company discover develop commercialize therapeutic advance care patient suffer lifethreatening disease worldwide product currently market market country worldwide research clinical program focus antiinfective include antiviral antifungal endeavor grow exist portfolio product proprietary clinical development program internal discovery program active product acquisition inlicense strategy worldwide headquarters foster city california european headquarters paris france incorporate delaware june january complete acquisition outstanding stock triangle pharmaceuticals inc triangle whollyowne subsidiary gilead aggregate preliminary purchase price million include cash pay outstanding stock fair value option assume estimate direct transaction cost employee termination cost triangle develop drug candidate antiviral area particular focus potential therapy hiv include aids hepatitis b virus triangle portfolio consist drug candidate clinical trial include emtricitabine treatment hiv infection emtricitabine treatment hepatitis b amdoxovir treatment hiv infection clevudine treatment hepatitis b triangle file marketing application emtricitabine treatment hiv united states european union product viread approve sale sell commercial team use combination antiretroviral agent treatment hiv infection european union european commercial team use combination antiretroviral agent treatment hiv infection patient experience early virological failure ambisome approve sale sell country treatment lifethreatening fungal infection country prevention infection market ambisome major country europe copromote ambisome fujisawa healthcare inc fujisawa hepsera approve sale sell commercial team treatment chronic hepatitis b hepsera receive marketing approval european union march tamiflu approve sale sell corporate partner hoffmannla roche roche country include european union prevention treatment influenza vistide approve sale sell commercial team gilead exus partner pharmacia corporation pharmacia country treatment cytomegalovirus cmv retinitis patient aid daunoxome approve sale sell country treatment aidsrelate kaposi sarcoma sell commercial team independent distributor abroad earn revenue million sale royalty product sale viread generate aggregate product sale royalty revenue million total revenue sale ambisome generate aggregate product sale royalty revenue million total revenue earn revenue sale royalty product million million million outside earn revenue sale royalty product million million million viread tenofovir disoproxil fumarate viread oral formulation nucleotide analogue reverse transcriptase inhibitor tenofovir df dose day combination therapy treat hiv infection adult drug work block reverse transcriptase enzyme involve replication hiv sell viread commercial team major european country european commercial team commercial operation food drug administration fda approve viread market october european agency evaluation medicinal product emea grant similar approval european union february viread approve use combination antiretroviral agent treatment hiv infection indication base analyse plasma hiv rna level cd cell count control study viread week duration study control doserange study viread week duration study study conduct treatmentexperienced adult evidence hiv viral replication despite ongoing antiretroviral therapy study patient previously receive antiretroviral therapy antiretroviralnave patient ongoing february report week datum ongoing threeyear randomize doubleblind clinical trial study design compare efficacy safety combination treatment regimen viread lamivudine tc efavirenz combination treatment regimen stavudine dt lamivudine efavirenz antiretroviralnave patient hiv infection datum study demonstrate treatmentnave patient receive viread experience substantially lipodystrophy low elevation fast cholesterol triglyceride level improved level limb fat weight gain achieve similar reduction hiv viral load increase cd cell count compare receive stavudine adverse event report percent patient include rash bacterial infection depression fever pneumonia low discontinuation rate approximately percent arm study week datum supplement week result study submit fda support use viread patient prior hiv therapy intend submit week datum potential inclusion european label predict fda emea accept interpretation datum approve label indicate viread use patient prior hiv therapy base datum approval week datum study recommend committee proprietary medicinal product cpmp february major challenge treat hivinfecte patient drug resistance exist therapy treat hiv infection aid rely similarlydesigne drug process patient develop resistance drug develop resistance drug class believe viread approve regulatory authority offer advantage approve hiv treatment available datum show patient develop resistance viread viread effective treat patient develop resistance therapy certain resistance datum obtain completion phase clinical trial similar resistance characteristic week datum study datum obtain limited phase clinical trial major concern hiv treatment convenience dose combination therapie positive impact require hivinfected patient numerous drug drug require multiple dose day time dietary restriction result inconvenience patient contribute patient miss dose adhere therapy viread approve administer oncedaily oral pill schedule appeal hivinfecte patient physicians hiv competitive landscape crowd complicated treatment trend continue evolve branded antihiv drug currently sell advance stage clinical development competition exclusive worldwide license patent right relate technology viread institute organic chemistry biochemistry academy sciences czech republic rega stichting vzw iocbrega obligate pay percentage net revenue sale viread european union country product approve patent protection iocbrega academic consulting relationshipsiocbrega ambisome amphotericin b liposome injection ambisome proprietary liposomal formulation amphotericin b amphotericin b powerful antifungal agent know ability treat invasive fungal infection cause fungal specie infection generally life threaten particularly patient depressed immune system aggressive chemotherapy regimen stem cell organ transplant hiv infection ambisome treatment effect include kidney toxicity study deliver amphotericin b proprietary liposomal formulation ambisome reduce rate severity kidney toxicity injectionrelate reaction allow patient receive high dose amphotericin b ambisome approve sale country include european union rest europe australia canada country middle east latin america asia countries ambisome approve include authorize topromote ambisome empirical treatment fungal infection ie treatment patient strong suspicion definite confirmation exist potentially lifethreatene invasive fungal infection remain country ambisome approve sale approve use firstline treatment invasive fungal infection secondline treatment conventional amphotericin b therapy fail conventional amphotericin b tolerate finally ambisome approve number country indication example cryptococcal meningitis aids patient prophylaxis liver transplant patient visceral leishmaniasis copromote ambisome fujisawa commercial team agreement fujisawa entitle percentage revenue generate sale provide fujisawa purchase ambisome manufacturing cost collaborative relationshipsfujisawa major european country australia sell ambisome international commercial team certain country sell ambisome independent distributor revenue ambisome europe expect case foreseeable future license commercial right ambisome japan sumitomo pharmaceuticals co ltd sumitomo exchange royalty generate activity ambisome approve sale japan ambisome face strong competition current competitor expect competitor treatment late stage clinical trial competition competition current expect competitor likely erode revenue receive sale ambisome hepsera adefovir dipivoxil hepsera oral formulation nucleotide analogue hbv dna polymerase inhibitor adefovir dipivoxil dosed day treat chronic hepatitis b hepatitis b cause highly contagious hepatitis b hbv virus cause acute liver failure patient develop chronic hepatitis b infection year lead complication cirrhosis liver cancer liver failure approximately patient result death accord recent estimate world health organization center disease control million people worldwide million people chronic hepatitis b million death attributable chronic hepatitis b worldwide year lead cause death worldwide hepsera disable hbv interfere activity enzyme know hbv polymerase necessary virus replicate application european union marketing authorization include datum separate phase clinical trial design evaluate safety effectiveness hepsera mg dosage treat patient hepatitis b virus phase trial design randomize doubleblind placebocontrolle study clinical site canada europe australia southeast asia study evaluate hepsera treat patient test positive hbv e antigen common type hepatitis b trial study evaluate hepsera treat patient type hepatitis b know precore mutant hepatitis b common southeast asian mediterranean country week adefovirassociate resistance mutation identify hepatitis b patient treat clinical trial suggest development resistance hepsera hepatitis b patient delay infrequent consequently believe hepsera resistance profile important drug treat chronic hepatitis b certain resistance datum obtain continue phase clinical trial hepsera continue resistance characteristic hepsera approve sale treatment chronic hepatitis b adult evidence active viral replication evidence persistent elevation serum aminotransferase alt ast histologically active liver disease commercial team sell hepsera march apply approval emea hepsera treatment chronic hepatitis b european union approval emea recommend cpmp november receive march plan sell hepsera major european union country european commercial team vaccine available prevent transmission hbv effective people chronically infect hbv expect vaccine widely available incidence new hepatitis b infection decrease advance prevention hepatitis b individual suffer chronic hepatitis b represent patient pool significant risk morbidity mortality underlie chronic viral infection chronic hepatitis b common china southeast asia december receive clinical trial permit initiate phase clinical trial china commence clinical trial june license rights commercialize hepsera solely treatment hepatitis b china korea japan taiwan rest asia latin america certain territory glaxosmithkline gsk approval commence phase clinical trial china hepsera grant class designation hepsera ultimately approve sale china gsk year market exclusivity hepsera respect competitor able begin clinical development adefovir dipivoxil follow approval receive chinese government approval phase study give approval forward phase program begin patient enrollment december exist therapy treat patient infect hbv compete hepsera treatment represent significant competition hepsera competition exclusive worldwide license patent right relate technology adefovir dipivoxil iocbrega pay percentage net revenue sale hepsera iocbrega country product patent protection include member states european union addition pay small variable percentage net revenue sales hepsera md anderson cancer center academic consulting relationship tamiflu oseltamivir phosphate tamiflu oral pill treatment prevention influenza b tamiflu class prescription drug call neuraminidase inhibitor act disable common strain flu virus prevent virus spread patient approve treatment influenza tamiflu show reduce duration flu adult average reduce severity flu symptom incidence secondary infection take approve prevention influenza study show tamiflu effective prevent development flu tamiflu approve country treatment influenza include japan european union treatment influenza childrenand adult tamiflu approve european union prevention influenza adolescent adult develop tamiflu roche roche exclusive right manufacture sell tamiflu subject obligation pay percentage net revenue roche generate tamiflu sale date roche sale tamiflu significantly expectation roche experience problem manufacture distribution tamiflu reduce net sale royalty base material effect revenue collaborative relationshipsroche product available treat flu time show effective safe neuraminidase inhibitor competition tamiflu market alternative influenza vaccination believe influenza vaccination remain effective method prevent flu vistide cidofovir injection vistide antiviral medication treatment cmv retinitis patient aid cmv retinitis condition characterize lesion form patient retina affect person weaken immune system common patient aid leave untreated cmv retinitis lead blindness vistide approve sale european union country demand vistide low product revenue immaterial commercial team sell vistide outside pharmacia exclusive right sell vistide pharmacia pay percentage revenue generate sale vistide collaborative relationshipspharmacia active agent vistide cidofovir consider government strategy deal potential bioterrorism attack involve smallpox lifethreatene highly communicable infectious disease laboratory test cidofovir demonstrate activity strain virus cause smallpox current clinical trial diluted smallpox vaccine conduct national institute allergy infectious disease cidofovir consider potential treatment vaccinia infection adverse reaction cause smallpox vaccine additionally national institutes health hold ind allow emergency use cidofovir smallpox outbreak marketing approval fda know efficacy cidofovir emergency use effect appear use cidofovir smallpox predict country government stockpile vistide treatment smallpox daunoxome daunorubicin citrate liposome injection daunoxome liposomal formulation anticancer agent daunorubicin firstline therapy treat patient suffer certain type hiv associate kaposi sarcoma disease characterize widely disseminate lesion skin mucous membrane lymph node viscera life threaten patient suffer aid daunoxome approve sale country sell daunoxome sell abroad independent distributor demand daunoxome low product revenue immaterial product clinical trial emtricitabine hiv acquire emtricitabine result acquisition triangle complete january nucleoside analogue emtricitabine show inhibitor hiv hbv replication laboratory study emtricitabine antiviral agent hiv strain obtain geographically diverse set hiv infect patient laboratory study show emtricitabine share crossresistance pattern lamivudine common resistance mutation agent reverse resistance hiv azt case phase clinical study emtricitabine complete collaboration agence nationale de recherche sur le sida anrs france study study ftc compare emtricitabine mg onceaday stavudine mg twiceaday combination didanosine mg onceaday efavirenz mg onceaday patient previous antiretroviral therapy july study unblinde recommendation independent datum safety monitoring board dsmb establish provide oversight study interim result evaluate study dsmb show emtricitabine arm statistically superior stavudine arm primary secondary endpoint safety efficacy eightyseven percent patient onceaday emtricitabine arm persistent virologic response month compare twicedaily stavudine arm patient emtricitabine arm significant improvement immunologic function view compelling difference favor emtricitabine arm dsmb recommend study unblinde patient offer regiman contain emtricitabine application marketing approval emtricitabine submit treatment hiv september european union december application accept review fda advise date review july emtricitabine hepatitis b emtricitabine show inhibitor hepatitis b virus replication patient chronically infect hbv currently phase clinical development emtricitabine treatment chronic hepatitis b development activity undertake emtricitabine treatment hiv assessment emtricitabine treatment hepatitis b amdoxovir acquire amdoxovir result acquisition triangle complete january amdoxovir purine dioxolane nucleoside offer advantage nucleoside currently market activity drug resistant virus exhibit laboratory study early triangle initiate phase clinical trial amdoxovir august fda place clinical development program amdoxovir partial clinical hold result concern lenticular opacity possible effect characterize clouding lens eye extent amdoxovir increase occurrence lenticular opacity patient receive amdoxovir unknown patient clinical study benefit amdoxovir new study involve patient fail treatment contain drug currently approve class antihiv medication require amdoxovir theirregimen continue treatment discussion fda partial clinical hold plan clevudine acquire clevudine result acquisition triangle complete january clevudine pyrimidine nucleoside analogue show potent inhibitor hepatitis b virus replication laboratory study november triangle initiate phase study currently conduct phase clinical trial clevudine treatment chronic hepatitis b chronic toxicology study complete reproductive toxicology study progress gs gs novel nucleotide analogue reverse transcriptase inhibitor process body yield tenofovir active chemical yield viread cell chemical composition gs allow cross cell membrane easily viread lead great potency viread quarter begin phase clinical trial gs treatment hiv infection research development research scientist foster city san dimas california durham north carolina engage discovery development new molecule technology hope lead new medicine novel formulation exist drug therapeutic focus area life threaten infectious disease total research development rd expense million compare million million nucleotide analogues scientist work proprietary nucleotide analogue develop treatment viral infection compounds treat viral infection interfere activity certain enzyme necessary virus grow believe small molecule nucleotide analogue offer advantage therapeutic molecule demonstrate ability work infect uninfected cell enable develop drug treat patient infected virus prevent healthy person infect place second drug develop molecule show treatment activity patient long period time available drug enable develop drug require frequent dose convenient patient hiv protease inhibitor evaluate number small molecule compound know protease inhibitor potential treatment hiv infection protease inhibitor act interfere activity protease enzyme like reverse transcriptase necessary replication hiv conduct number preclinical experiment compound demonstrate potent antiviral activity lead candidate gs currently undergo extensive preclinical evaluation antiviral research undertake additional research area treatment viral disease effort focus potential target hiv therapeutic drug liposome scientist focus apply proprietary liposomal drug delivery technology develop safe effective convenient drug liposome submicroscopic hollow sphere drug pack believe research support belief influence way compound release distribute body place liposome turn improve safety treatment benefit compound commercial operation international commercial sale operation marketing subsidiary united kingdom germany italy spain france portugal greece australia commercial team promote sell viread hepsera ambisome viread ambisome europe australia ambisome sell fujisawa sell vistide daunoxome commercial partner pharmacia sell vistide outside sell daunoxome outside independent distributor commercial partner roche promote sell tamiflu sell commercial team promote viread hepsera direct field contact physician hospital clinic healthcare provider involve treatment patient hiv viread chronic hepatitis b hepsera promote ambisome infectious disease specialist hospital home health care provider cancer specialist international commercial operation europe australia european commercial team support medical operational financial regulatory manufacturing human resource personnel locate primarily european headquarters paris france australian commercial team support worldwide headquarters foster city california country outside agreement thirdparty distributor include distributor certain country market operation promote sell distribute viread ambisome daunoxome international distribution agreement generally provide distributor exclusive right sell viread ambisome daunoxome particular country country specify period time january announce program pursuant sell viread cost country africa country designate develop country united nations take step ensure viread product sell program serve patient develop world divert market international distributionto support expand commercialization viread hepsera significantly increase sale force devote additional marketing resource improve coverage healthcare professional treat hivinfecte hbvinfecte patient significantly increase size commercial operation europe manage commercialization viread anticipate commercialization hepsera european union current intention retain commercial right hepsera market directly distributor canada europe australia new zealand turkey april enter licensing agreement gsk gsk receive right commercialize hepsera asia latin america africa certain territory agreement retain right hepsera canada eastern western europe australia new zealand turkey gsk receive exclusive right develop hepsera solely treatment hepatitis b country significant include china korea japan taiwan gsk responsibility development commercialization hepsera territorie viread hepsera vistide returnable original unopened container year expiration date damage receive customer customer return ambisome daunoxome shelf life expire product damage defective customer receive ambisome approve shelf life month month european country daunoxome shelf life week european country viread shelf life month european union hepsera shelf life month additionally certain governmental agency customer state aids drug assistance program entitle receive discount require provide rebate state medicaid programs date return rebate discount material financial result fujisawa establish return policy ambisome north america roche establish return policy tamiflu end flu season significant return tamiflu roche reduce net sale royalty roche base collaborative relationship business strategy establish collaboration company assist clinical development andor commercialization certain product product candidate provide support research program evaluate opportunity acquire company product right product technology complementary business accounting relationship find note consolidated financial statement include report exist collaborative relationship follow anadys pharmaceuticals inc june enter collaboration anadys pharmaceuticals inc discover novel antiviral compound addition access fee milestone payment subject limitation gilead pay anadys royalty product develop research collaboration archemix corporation october enter agreement archemix corporation archemix agreement grant archemix exclusive sublicense selex technology identify aptamer subject exclusion development area right grant forfeited right selex technology derive license university license equity holdings inc ulehi successor university technology corporation predecessor university research corporation financial term agreement archemix provide lump sum payment total million archemix payment receive warrant purchase archemix stock agreement require agreement ulehi share portion cash payment warrant ulehi academic consulting relationshipsuniversity license equity holdings inc bukwang pharm ind co ltd february triangle enter acquire acquisition triangle license agreement bukwang pharm ind co ltd bukwang pursuant receive exclusive license bukwang right clevudine use hepatitis b field human antiviral application license include country world korea license obligate milestone royalty payment bukwang include annual minimum royalty begin year fda registration grant fdaapprove product incorporate clevudine technology glaxosmithkline april enter licensing agreement gsk give exclusive right commercialize hepsera solely treatment hepatitis b asia latin america certain territory addition fee milestone payment contract revenue gsk require pay percentage revenue generate sale hepsera license territory agreement gsk require enter clinical commercial supply agreement gsk require arrange supply clinical commercial requirement fully burden cost subject reasonable forecasting order procedure agreement gsk expire individual country basis later patent expiration year commercial sale particular country addition gsk right electively terminate agreement month notice gilead subject fee elective termination circumstance early term agreement eyetech pharmaceutical march enter agreement eyetech pharmaceuticals inc eyetech relate product name macugen develop treatment agerelate macular degeneration amd diabetic macular edema dme gilead invent compound macugen base nx selex technology license gilead ulehi academic consulting relationshipsuniversity license equity holdings inc gilead license nx eyetech develop macugen license gilead eyetech require pay fee milestone payment percentage revenue generate worldwide sale macugen agreement eyetech expire later year commercial sale product develop date patent expire agreement eyetech grant pfizer sublicense relate macugen december december connection sublicense gilead agree enter license pfizer term contain agreement eyetech rochein enter collaboration agreement roche grant roche exclusive worldwide right tamiflu proprietary influenza neuraminidase inhibitor december receive license fee milestone payment roche total million relate execution agreement regulatory filing approval tamiflu roche fund research development cost tamiflu include reimbursement million period january december agreement roche responsible pricing manufacturing promote sell tamiflu worldwide basis pay percentage net revenue sale tamiflu subject reduction certain define manufacturing cost agreement roche terminate individual country basis later patent expiration year commercial sale particular country addition roche right terminate agreement entirety individual country basis prior expiration time month notice fujisawa enter agreement grant fujisawa exclusive right promote sell ambisome canada primary responsibility promote sell ambisome gilead copromoter fujisawa pay approximately fujisawa net revenue sale ambisome reserve right promote sell ambisome rest world pay fujisawa net revenue ambisome sale significant asian market include japan korea taiwan china india manufacture ambisome sell worldwide sell ambisome fujisawa sale price equal cost manufacture product sale canada price equal cost manufacture product plus specify percentage agreement fujisawa terminate patent cover ambisome japan expire osi pharmaceutical december sell osi pharmaceutical osi pipeline clinical stage oncology product relate intellectual property boulder colorado operation consideration asset receive osi million cash share osi common stock additionally osi pay additional million cash combination cash osi common stock achievement osi certain milestone relate development nx advanced oncology product candidate separately manufacture agreement osi agree produce osi liposomal formulation product include nx manufacturing facility san dimas california pharmacia enter agreement pharmacia relate vistide agreement pharmacia exclusive right market sell vistide country outside subject payment percentage net revenue require sell pharmacia bulk vistide maintain vistide patent agreement pharmacia expire individual country basis patent expiration year commercial sale country product cover patent addition pharmacia terminate agreement month notice notice individual country basis month apply marketing approval competitive product sumitomo enter agreement sumitomo give sumitomo exclusive right develop market ambisome japan addition milestone payment sumitomo require pay percentage revenue generate japanese sale ambisome ambisome approve sale japan manufacture ambisome sale sumitomo japan price charge sumitomo supply ambisome percentage revenue required pay determined price ambisome japan agreement sumitomo terminate later patent expiration japan year commercial sale japan termination agreement cubist pharmaceutical cidecin september jointly announce cubist pharmaceutical inc termination licensing agreement commercialization cidecin daptomycin injection oral formulation daptomycin terminate license agreement execute january grant exclusive commercialization right product european country follow regulatory approval term termination agreement owe future payment cubist cubist reacquire european right product academic consulting relationship supplement research development effort regular business enter arrangement university medical research institution arrangement provide right patent patent application technology own institution return payment fee relate use right emory university university georgia research foundation inc emtricitabine april triangle obtain acquire acquisition triangle exclusive worldwide license emory university right purify form emtricitabine use hiv hepatitis b field obligate certain milestone royalty payment emory include annual minimum royalty begin year fda registration grant antihiv product incorporate emtricitabine technology year registration grant antihepatitis b product incorporate emtricitabine technology certain major market country hiv hepatitis b indication respectively triangle begin pay license maintenance fee development milestone achieve emory gsk settle litigation pende united states district court relate emtricitabine exclusive licensee foreign patent patent application file burrough wellcome co use emtricitabine treat hepatitis b license settlement agreement emory give access development clinical datum drug substance hold gsk relate emtricitabine emory gsk shire pharmaceuticals group plc shire settle worldwide patent dispute involve lamivudine emtricitabine theterm settlement emory receive exclusive license shire shire patent relate emtricitabine method use manufacture shire gsk receive exclusive license emory patent relate lamivudine term license agreement emory automatically acquire exclusive sublicense shire patent relate emtricitabine grant term settlement resolve previously pende patent dispute emtricitabine amdoxovir march triangle enter acquire acquisition triangle license agreement emory university georgia research foundation inc ugrf pursuant receive exclusive worldwide license emory ugrf right series nucleoside analogue include amdoxovir dxg ie active antihiv agent use hiv hepatitis b field obligate milestone royalty payment emory ugrf march triangle begin pay license maintenance fee development milestone achieve begin year fda registration grant fdaapprove product incorporate amdoxovir technology require pay emory ugrf minimum annual royalty august triangle resolve outstanding patent dispute involve amdoxovir shire term settlement emory ugrf receive exclusive license shire patent right cover amdoxovir method use manufacture term license agreement acquire exclusive sublicense right exchange obligation pay shire incremental royalty future amdoxovir sale settlement agreement emory ugrf gilead grant shire exclusive license patent right bch method use manufacture license agreement emory terminate late patent expiration expiration obligation pay royalty addition right terminate agreement entirety respect indication hiv hbv country prior expiration time day notice md anderson cancer center enter agreement md anderson cancer center relate hepsera agreement currently pay md anderson cancer center percentage net revenue base sale hepsera agreement md anderson cancer center terminate later patent expiration year commercial sale iocbrega enter agreement iocbrega relate viread hepsera vistide agreement receive iocbrega exclusive right manufacture use sell nucleotide compound cover agreement currently pay net revenue base sale viread hepsera vistide iocbrega agreement iocbrega terminate individual country basis later patent expiration year commercial sale addition iocbrega terminate license particular product key market absence commercial sale product month regulatory approval university license equity holdings inc ongoing collaborative arrangement university license equity holdings inc ulehi technology hold company university colorado boulder relate selex technology identify aptamer arrangement ulehi grant present future right invention cover patent patent application selex technology improvement selex technology make discover oligonucleotide molecule make selex technology computer software relate selex technology require pay ulehi certain variable royalty base revenue generate sale product derive selex technology develop world collaboration bill melinda gates foundation family health international october enter agreement bill melinda gates foundation family health international fhi provide viread fhi multinational clinical trial evaluate viread effectiveness method reduce risk hiv infection sexually active adult regularly expose hiv clinical trial conduct fhi fund million threeyear grant gates foundation dart study november enter collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection fiveyear clinical study conduct mrc antiretroviral hiv therapy africa trial call dart trial development antiretroviral therapy africa aim study clinical versus laboratory monitoring practice structure treatment interruption versus continuous antiretroviral therapy adult hiv infection subsaharan africa provide viread cost dart study institute world health january enter agreement institute world health pursuant provide ambisome cost phase clinical trial evaluate ambisome treatment visceral leishmaniasis paromomycin india great global burden visceral leishmaniasis clinical trial conduct institute world health partnership world health organization international distribution agreement distributor europe asia latin america middle east africa grant distributor exclusive right sell ambisome case daunoxome particular country country specify period time agreement provide collaborative effort distributor obtain regulatory approval product particular country marketing product country agreement establish price distributor pay product require deliver quantity product order distributor enter similar distribution agreement viread country promote sell directly january announce program pursuant supply viread cost country africa country designate develop country united nations humanitarian effort recognition extreme impact hiv disease resourcepoor country world case hiv locate country take step ensure viread product sell program serve patient develop world divert market manufacture ambisome daunoxome manufacture ambisome daunoxome commercial quantity separate adjacent facility san dimas california medicines control agency united kingdom fda approve commercial production ambisome daunoxome facility produce import ambisome daunoxome european union manufacturing facility dublin ireland perform quality control testing final labeling packaging distribution european union use commercially available material equipment manufacture product currently obtain amphotericin b use manufacture ambisome daunorubicin hcl distearoylphosphatidylcholine use manufacture daunoxome cholesterol use manufacture ambisome daunoxome single approve supplier ambisome sell freezedrie product currently freezedry ambisome san dimas manufacturing facility use party freeze dry additional product give current projection growth ambisome demand sufficient capacity meet future demand option instal additional freezedrying capacity san dimas additional supply necessary prove unable install additional freeze drying capacity san dimas locate appropriate party meet need ability meet increase ambisome demand diminish manufacture liposomal product particularly complex process new liposomal product develop require unique complex variation manufacturing process antiviral product contract party manufacture antiviral drug clinical commercial purpose include viread hepsera vistide emtricitabine amdoxovir clevudine manufacture viread tablet single contract manufacturer european union sale distribution territory addition second contract manufacturer europe european union distribute product approve respective agency obtain qualification seek qualification european union contract manufacturer active ingredient hepsera contract manufacturer final hepsera drug product commercial supply seek qualify second supplier january roche announce production problem liquid suspension form tamiflu approve treatment child young yearold available liquid suspension form tamiflu return market time flu season production issue affect availability tablet form tamiflu adult adolescent year old japan flu season particularly severe roche sublicensee chugai corporation unable meet heighten demand satisfactorily january chugai issue press release attribute failure manufacturing problem problem japan reduce net sale royalty roche base date production commercialization issue material effect earning expect material effect earning future enter agreement abbott manufacture emtricitabine bulk drug substance final drug product currently seek qualification abbott european union contract manufacturer seek qualification european union second contract manufacturer emtricitabine bulk drug substance abbott recent history violation current good manufacturing practice regulation cite fda work correction fda consent decree fda conduct preapproval inspection abbott new drug application emtricitabine issue form observation abbott december january abbott submit response form observation fda deem abbott response form observation inadequate abbott unable supply initial launch quantity emtricitabine timely manner emtricitabine launch delay supplier approve fda european union manufacture cidofovir vistide single fda emea approve supplier final vistide drug product commercialscale manufacturing facility antiviral product current plan establish facility future antiviral product need develop additional manufacturing capability establish additional party supplier order manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale unable develop manufacturing capability internally contract large scale manufacturing party acceptable term future antiviral product ability conduct largescale clinical trial meet customer demand commercial product adversely affect believe technology use manufacture product compound proprietary antiviral product disclose necessary aspect technology contract manufacturer enable manufacture product compound agreement manufacturer intend restrict reveal technology certain manufacturer comply restriction addition manufacturer develop technology relate work perform need manufacture product compound require enter agreement manufacturer want use technology allow manufacturer use technology manufacturer refuse allow use technology demand term use technology acceptable believe compliance material environmental regulation relate manufacture product patent proprietary right patent proprietary right important business properly design enforceable patent difficult ourcompetitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection internationally file additional patent application appropriate cover improvement compound product technology rely trade secret internal knowhow technological innovation agreement party develop maintain protect competitive position ability competitive depend success strategy number patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent follow table show actual estimate expiration date europe primary patent patent issue pende application cover compound market product product candidate patent expiration european patent expiration product viread hepsera ambisome tamiflu vistide daunoxome product candidate emtricitabine amdoxovir clevudine application patent pende patent application issue patent protection date indicate instead rely patent expire early example european patent viread issue patent expire provide protection patent cover viread hepsera vistide emtricitabine clevudine amdoxovir hold party acquire exclusive right patent agreement party collaborative relationship academic consulting relationship patent cover active ingredient ambisome daunoxome instead hold patent liposomal formulation compound protect formulation trade secret patent filing cover form hepsera china certain asian country application pende asian country include china relate specific form formulation hepsera asia major market hbv therapy obtain patent compound year obtain marketing approval limit time prevent company develop compound reduce value product apply patent term extension example extension patent vistide grant number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain important infringe patent proprietary right violate agreement grant proprietary right infringe patent violate agreement prevent develop selling product process cover patent agreement require obtain license party allow use technology certain require obtain license thirdparty technology obtain reasonable cost able obtain require license adversely affect patent application confidential period time include patent issue pende patent application patent eventually issue prevent develop sell certain product obtain license use patent technology patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation reexamination proceeding enforcement validity exist patent future patent invalidate patent substantially reduce protection addition pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product develop rely unpatented trade secret improvement unpatente internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor research development agreement invention discover certain case jointly own corporate partner case exclusive property difficult determine own particular invention dispute arise invention competition product development program target number disease condition include viral fungal bacterial infection commercially available product disease large number company institution spend considerable amount money resource todevelop additional product treat disease current product compete available product base primarily efficacy safety tolerability acceptance doctor patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing adaptability mode dose product market future compete product offer competitor competitor introduce datum show improved characteristic product improve increase marketing effort simply low price product sale product decrease certain product develop future compare favorably product offer competitor exist future product compare favorably new product develop competitor ability competitive depend ability attract retain qualified personnel obtain patent protection develop proprietary product process secure sufficient capital resource substantial period take develop product viread hiv competitive landscape crowd complicated treatment trend continue evolve grow number antihiv drug currently sell advance stage clinical development brand drug available zerit stavudine dt sell bristolmyer squibb bms fix combination product combivir azt tc trizivir azt tc abc sell gsk represent direct competition viread company process launch formulation exist drug indicate fda oncedaily oral dosing include gsk mg dose epivir tc bms new extend release formulation zerit antiretroviral product candidate expect enter market year include atazanivir qd protease inhibitor bms fuzeon injectable integrase inhibitor rochetrimeris gsk pursue oncedaily dose ziagen abacavir new fix dose combination ziagen epivir company compete hiv therapeutic category pfizer merck boehringeringelheim abbott laboratories ambisome ambisome face strong competition current expect competitor current competitor include conventional amphotericin b bms numerous generic manufacturer caspofungin product develop merck market cancida caspofungin voriconazole develop pfizer market vfend lipidbase amphotericin b product approve europe include abelcet sell enzon corp canada japan elan corporation marketing distribution partner country amphotec sell intermune pharmaceutical inc presently unapproved expect competitor include class treatment call echinocandin include fujisawa micafungin receive marketing approval japan october submission regulatory approval canada anidulafungin versicor inc product candidate evaluate multiple latestage clinical trial finally schere plough develop noxafil posaconazole currently phase trial competition current expect competitor erode likely continue erode revenue receive sale ambisome hepsera hepsera face significant competition exist therapy treat patient infect hbv significantly epivirhbv lamivudine develop collaboration shire pharmaceutical sell gsk major country north south america europe asia orally administer nucleoside analogue inhibit hbv dna polymerase introna interferon alfab sell schere plough major country north south america europe asia introna injectable drug immunomodulatory effect hepsera face competition clinicalstage candidate include bristolmyer squibb entecavir idenix ldt oral nucleoside analogue currently phase trial competition include roche pegasys pegylate interferon alfaa currently study chronic hepatitis btamiflu tamiflu compete relenza antiflu drug sell gsk relenza neuraminidase inhibitor deliver orallyinhale dry powder addition biocryst pharmaceutical develop neuraminidase inhibitor antiflu drug peramivir represent significant competition fda approve drug administer oncedaily pill oppose tamiflu take twice daily treatment certain tamiflu compare favorably drug base performance price length dose effect criterion vistide vistide compete number drug treat cmv retinitis include ganciclovir sell intravenous oral formulation roche ocular implant bausch lomb incorporate valganciclovir market roche foscarnet intravenous drug sell astrazeneca formivirsen drug inject directly eye sell cibavision daunoxome daunoxome compete expect compete number drug approve await approval treatment kaposi sarcoma europe include doxil product ortho biotech like daunoxome sell liposomal formulation number company pursue development technology competitive research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently biopharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program anticipate face increase competition future competitor introduce new product market new technology available determine exist product new product competitor develop effective effectively market sell develop competitive product render technology product obsolete noncompetitive recover money resource develop product government regulation operation activity subject extensive regulation numerous government authority countrie drug subject rigorous fda regulation federal food drug cosmetic act federal state statute regulation govern testing manufacture safety effectiveness labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume fda approve drug sell general process approval follow preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug potential safety benefit submit datum fda investigational new drug application ind seek approval test compound human clinical trial fda accept investigational new drug application study drug human clinical trial determine drug safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug give small number healthy human subject patient test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug give limited patient population determine effect drug treating disease well dose drug possible effect safety risk drug phase compound appear effective safe phase clinical trial phase clinical trial commence confirm result phase clinical trial longterm involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug uncommon drug appear promise phase clinical trial fail rigorous reliable phase clinical trial fda approval process believe datum phase clinical trial adequate level safety effectiveness file new drug application nda fda seek approval sell drug particular use fda review nda hold public hear independent advisory committee expert advisor ask additional question drug committee make recommendation fda bind fda generally follow fda fda agree compound require level safety effectiveness particular use allow sell drug use unusual fda reject application believe drug safe effective believe datum submit reliable conclusive point process development drug stop number reason include safety concern lack treatment benefit certain clinical trial conduct include viread emtricitabine hiv infection hepsera chronic hepatitis b conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit fda require complete additional testing provide additional data information improve manufacturing process procedure facility require extensive postmarketing test surveillance monitor safety benefit product candidate determine new drug application contain adequate evidence safety benefit drug addition fda approve drug limit use drug approval withdraw fda believe comply regulatory standard problemsare uncover occur approval addition obtain fda approval drug manufacturing facility drug sell include company manufacture drug approve fda subject periodic inspection fda foreign establishment manufacture product sell approve fda subject periodic regulatory inspection manufacturing facility locate california include san dimas facility foster city facility license state california compliance local regulatory requirement drug treat lifethreatening disease condition adequately address exist drug designate fast track product fda eligible priority month review accelerate approval case viread drug receive accelerated approval monitor postmarkete clinical trial order confirm safety benefit drug subject federal state local regulation workplace safety protection environment use hazardous material chemical viruse radioactive compound research development activity eliminate risk accidental contamination injury material misuse accident involve material lead significant litigation fine penalty drug subject extensive regulation outside european union centralize approval procedure authorize marketing product country european union include major country europe procedure decentralized system approval country european union obtain approval country european union simplify application process approval centralized procedure pricing reimbursement approval require country vistide viread approve european union centralize procedure viread hiv drug review accelerate approval european union hepsera receive traditional review emtricitabine pricing reimbursement insurance company health maintenance organization hmos thirdparty payor government seek limit charge drug example certain foreign market pricing negotiation require obtain approval product expect continue number federal state proposal implement drug price control addition manage care organization common continue seek low drug price announcement proposal effort cause stock price low proposal adopt revenue decrease ability sell drug depend availability reimbursement government private insurance company government insurance company demand rebate predetermine discount list price expect product develop particularly aid indication subject reimbursement issue certain product obtain regulatory approval reimburse government insurance company regulatory approval price generally require foreign country particular certain country condition approval product agreement seller sell product certain price country past require price reduction connection product approval certain regulatory authority future establish low price regulatory action reduce price product country practical effect require reduce price country european government notably germany italy implement consider legislation require pharmaceutical company sell product subject reimbursement mandatory discount mandatory discount reduce revenue receive drug sale certain develop country significantly affect hiv aids parallel import generic competition occur adversely affect revenue sale market share viread management change march announce john f milligan phd promote senior vice president chief financial officer report directly ceo restructure combine responsibility corporate function support strategic financial communication technological planning broaden senior management role corporate development finance corporate communication information technology group centralize leadership dr milligan addition announce time completion organization change include alignment manufacturing group san dimas operational area report mark l perry executive vice president operation establish paris france headquarters european operation employee february approximately fulltime employee believe good relation employee website website address wwwgileadcom available free charge website annual report quarterly report form q current report form k amendment report soon reasonably practicable filing provide hyperlink edgar website directly report risk factor affect gilead evaluate business carefully consider follow risk addition information report follow risk materially adversely affect business operating result financial condition viread maintain increase market acceptance result operation suffer rely sale viread significant portion operating income viread face extremely competitive marketplace number drug treat hiv infection aid currently sell advanced stage clinical development include product currently sell company significant competitor hivaid market gsk bristolmyer squibb roche pfizer merck boehringeringelheim abbott laboratories competitor potential competitor substantially great resource resource include great experience promote market hiv drug superior product development capabilitie financial scientific manufacturing marketing managerial human resource order viread continue success maintain expand position marketplace competitor drug viread market penetration limit particularly use treatmentnave patient give data datum support marketing approval reflect use viread treatmentexperience patient population obtain datum safety efficacy viread treatment nave patient regulatory authority allow include datum label viread marketing effort unsuccessful include information viread use treatmentnave patient viread labeling datum unsuccessful convincing physician prescribe viread treatmentnave patient government reimburser private insurance company pay viread prescribe patient prior hiv therapy viread maintain increase market acceptance result operation suffer significant reduction viread ambisome hepsera sale significantly reduce operating income require scale manufacturing operation reduce sale force viread product sale year end december million million total revenue respectively expect product sale viread constitute substantial total revenue foreseeable future ambisome sale year end december million million million total revenue expect revenue sale ambisome continue provide material portion total product revenue hepsera product sale begin september year end december approximately million total revenue expect product sale hepsera constitute substantial total revenue foreseeable future accordingly foreseeable future expect continue rely heavily sale viread ambisome hepsera support exist manufacturing sale infrastructure provide operating income fund significant portion administrative research development expenditure significant reduction sale viread ambisome hepsera result introduction competitive product hurt business scale manufacturing operation reduce sale force safety issue arise market product significantly reduce limit sale adversely affect result operation datum support marketing approval product include viread ambisome hepsera form basis safety warning product label obtain control clinical trial limit duration case viread limited postapproval use follow approval product long period time patient take numerous medicine underlie health problem monitor dose compliance new safety issue report postmarkete use rule contributory role product required provide additional warning label narrow approve indication reduce market acceptance product example observe kidney toxicity clinical trial viread kidney toxicity report postapproval use viread viread label update include warn safety issue market product arise face potential product liability claim sale product halted regulatory authority similarly discontinue development adefovir dipivoxil mg treatment hiv infection safety benefit concern arise study doubleblind placebo control study adefovir dipivoxil mg demonstrate safety efficacy treatment patient chronic hepatitis b study show adefovir dipivoxil significantly effective hbv hiv allow use low dose mg adefovir dipivoxil hepsera treatment hiv infection mg dose adefovir dipivoxil hepsera associate significant kidney toxicity clinical trial date patient preexist kidney problem take drug know cause kidney toxicity fda grant marketing approval hepsera certain result phase clinical study hepsera demonstrate satisfaction regulatory agency include european union hepsera safe effective treatment chronic hepatitis b hepsera new drug gain significant market acceptance hepsera new drug face competitive marketplace currently drug sell treatment chronic hepatitis b potential drug late stage clinical development competitor potential competitor substantially great resource resource include great experience promote marketing pharmaceutical include hbv drug superior product development capabilitie great financial scientific manufacturing marketing managerial human resource order hepsera successful establish marketplace competitor drug early determine hepsera achieve significant market acceptance welldevelope market generally accept treatment strategy hepatitis b market sell drug treatment chronic hepatitis b successful able develop therapeutic market effectively long term use hepsera reveal safety issue development resistance hepsera patient marketing effort unsuccessful hepsera turn safety resistance issue unsuccessful convincing physician prescribe hepsera patient government reimburser private insurance company pay hepsera hepsera gain significant market acceptance expect future result operation suffer fiscal year year operating profitability able maintain profitability sustainable basis profitable operating basis year continue profitable future expect merger triangle reduce earning effect earning increase earning certain estimate correct december accumulate deficit approximately million loss result principally expense associate research development program less extent sale general administrative expense operating result adversely affect reduce sale product increase marketing development expense acquisition product company triangle unprofitable time acquisition result risk describe report develop drug treat hiv infection aid relate condition change regulatory commercial environment hiv infection aid therapy harm businessseveral product product development address hiv infection aid relate condition product include viread emtricitabine hiv infection aid vistide cmv retinitis daunoxome hivassociate kaposi sarcoma develop product base current policy current marketplace hiv infection aid therapie prediction future policy future marketplace therapie business subject substantial risk policy market change quickly unpredictably way impair ability maintain regulatory approval commercial acceptance product operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis achieve continued compliance delay commercialization product product develop approve marketing sale regulatory authority subject extensive regulation fda comparable regulatory agency country continue clinical trial ambisome viread hepsera currently approve additional use anticipate conduct variety clinical trial file marketing approval additional product year product fail receive marketing approval timely basis certain hepsera approve european union regulatory authority countrie hepsera receive marketing approval country significant limitation place use certain emtricitabine approve european union marketing approval significant limitation use certain able obtain regulatory approval necessary expand commercial effort new market failure delay limitation regulatory change action recall delay commercialization product adversely affect result operation addition product market product manufacturer subject continual review later discovery previously unknown problem product manufacture production thirdparty manufacturer result restriction product manufacture product include withdrawal product market fail comply applicable regulatory requirement subject penalty include fine suspension regulatory approval product recall seizure product criminal prosecution result clinical trial uncertain support regulatory approval product require demonstrate safety effectiveness product develop intend use extensive preclinical study clinical trial order obtain regulatory approval product result preclinical early clinical study accurately predict result later large scale clinical trial reason include preliminary result indicative effectiveness clinical trial achieve desire result clinical trial reveal unduly harmful effect drug effective drug delivery system desire indication successfully complete largescale clinical trial result marketable product reason include potential product show safe effective regulatory authority disagree result design study trial potential product difficult develop commercially viable product number company industry suffer setback advance clinical trial despite promise result early trial end unable develop additional marketable product delay enrol patient develop suitable protocol clinical trial increase cost delay regulatory approval rate completion clinical trial depend rate patient enrollment substantial competition enroll patient clinical trial drug development competition delay clinical trial past addition recent improvement exist drug therapy particularly hiv hepatitis b difficult enroll patient clinical trial patient population choose enroll clinical trial sponsor company choose alternative therapy delay plan patient enrollment result increase development cost delay regulatory approval clinical trial carry protocol acceptable regulatory authority committee responsible clinical study site study conduct delay prepare protocol receive approval delay start finish clinical trial addition feedback regulatory authority result early stage clinical study require modification delay later stage clinical trial type delay result increase development cost delay regulatory approval approximately half product sale occur outside currency fluctuation impair financial result significant percentage product sale denominate foreign currency increase value dollar foreign currency past reduce future reduce dollar equivalent sale negatively impact financial condition result operation effective january begin use foreign currency forward contract hedge percentage forecast international sale primarily denominate euro currency hedge portion account receivable balance denominate foreign currency reduce eliminate exposure currency fluctuation date sale record date cash collected additionally mitigate impact currency rate fluctuation cash outflow certain foreign currencydenominate raw material purchase enter foreign exchange forward contract hedge foreign currency denominate account payable use forward contract reduce impact foreign currency fluctuation future result certain effort successful fluctuation adversely affect result operationswe face credit risk international account receivable subject credit risk account receivable relate european product sale european product sale government own support customer greece spain portugal italy subject significant payment delay government funding reimbursement practice significant change occur reimbursement practice european government government funding unavailable financial position result operation adversely affect product development expense cause operating expense fluctuate quarter quarter clinical trial require regulatory approval product extremely expensive difficult accurately predict control timing expense quarter quarter uneven unexpected activity program cause operating result fluctuate quarter quarter depend relationship company sale marketing performance revenue failure maintain relationship negatively impact business rely number significant collaborative relationship major pharmaceutical company sale marketing performance include collaboration fujisawa sumitomo ambisome gsk hepsera roche tamiflu pharmacia vistide certain country rely international distributor sale ambisome viread european country intend rely international distributor sale hepsera relationship involve clinical development product partner reliance collaborative relationship pose number risk include able control corporate partner devote sufficient resource program product dispute arise future respect ownership right technology develop corporate partner disagreement corporate partner lead delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor corporate partner marketing right choose devote few resource marketing product product development distributor corporate partner unable pay give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue exist product include viread hepsera ambisome tamiflu decline january roche announce production problem liquid suspension form tamiflu approve treatment child young year old available liquid suspension form tamiflu return market time flu season production issue affect availability tablet form tamiflu adult adolescent year old japan flu season particularly severe roche sublicensee chugai corporation unable meet heighten demand satisfactorily january chugai issue press release attribute failure manufacturing problem problem japan reduce net sale royalty roche base april licensing agreement gsk give gsk right control clinical regulatory development commercialization hepsera territory include asia africa latin america include major market hepsera china japan taiwan korea success hepsera territory depend entirely effort gsk receive royalty gsk equal percentage net sale gsk gsk fail devote sufficient resource succeed develop commercialize hepsera territory potential revenue sale hepsera substantially reduce exist product product development accept physician insurer patient ability product achieve sustain market acceptance country approve marketing depend scope regulatory approval government authority manage care organization adequately reimburse patient use product addition need convince medical patient advocacy community effectiveness product treat disease safety product administer patient advantage product competitive product physician patient patient advocate payor medical community general accept use product develop product accept result operation suffer company target disease condition competitive product company significantly reduce themarket acceptance product product development program target number disease condition include viral infection fungal infection commercially available product disease certain product wellestablishe therapy generate substantial sale addition large number company institution conduct wellfunde research development activity direct develop treatment disease product currently market development competitor technology product obsolete noncompetitive expect competition treatment disease increase future new product enter market advanced technology available compete license acquire technology company plan supply viread cost certain develop country reduce viread gross profit margin rise unforeseen liability launch distribution program pursuant supply viread cost country africa country designate develop country united nations receive profit viread supply program reduce viread product gross profit margin reduction depend volume viread flow program predict certainty additionally supply distribution drug resourcepoor environment complicated undertaking program develop face unforeseen challenge risk rise unforeseen liability exist product subject reimbursement government agency party pharmaceutical pricing reimbursement pressure reduce profitability successful commercialization product depend availability governmental party payor reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement government authority thirdparty payor increasingly challenge price medical product service particularly innovative new product therapy result low average sale price example majority sale ambisome vistide daunoxome significant percentage sale viread hepsera subject reimbursement government agency result significant discount list price rebate obligation business adversely affect increase international pricing pressure pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general recent year new legislation propose federal state level effect major change health care system nationally state level proposal include prescription drug benefit proposal medicare beneficiary introduce congress federal reform legislation state enact health care reform legislation federal state development possible predict exact nature legislative health care reform result operation adversely affect reform europe success hepsera approve sale tamiflu viread depend largely obtain maintain government reimbursement europe european country include united kingdom france patient reluctant pay prescription drug pocket expect success product development particularly europe depend ability obtain reimbursement reimbursement available reimbursement policy adversely affect ability sell product profitable basis addition international market government control price prescription pharmaceutical market regulatory marketing approval receive pricing negotiation governmental authority month long sale compete product attempt gain market share introductory pricing program competitor require low price country adversely affect result operation foreign government passed consider legislation require sell product subject reimbursement mandatory discount product revenue reduce import country product available low price sale country relatively high price reduce product import country low price market case pharmaceutical product sell steeply discount price develop world reexporte european country resold high price happen product particularly viread agree provide cost country africa country designate develop country united nations revenue adversely affect addition european union require permit cross border sale allow buyer country governmentapprove price product relatively high purchase product legally country sell low price crossborder sale adversely affect revenue able obtain effective patent protect technology use competitor patent company require stop pay use require technology success depend significant degree ability obtain patent license patent right preserve trade secret operate infringe proprietary right right foreign issue patent file continue file patent application abroad relate technology risk patent issue application patent sufficient protect technology patent application confidential period time patent issue result know competitor file patent application technology cover pende application certain invent technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete patent patent filing china certain asian country cover form adefovir dipivoxil active ingredient hepsera dohave application pende asian country relate form formulation adefovir dipivoxil asia major market therapy hepatitis b indication hepsera develop obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale commercial value product limit addition patent provide adequate protection certain country africa asia include china competitor file patent application cover technology participate interference proceeding litigation determine right patent litigation interference proceeding expensive successful success depend large ability operate infringe patent proprietary right party infringe patent prevent commercialize product require obtain license party certain able obtain alternative technology require license obtain technology license certain term reasonable fail obtain license alternative technology unable develop commercialize product addition use significant proprietary technology rely unpatented trade secret proprietary knowhow protect certain aspect production technology trade secret know independently discover competitor country require grant compulsory license hiv product face generic competition hiv product number develop country government official group suggest pharmaceutical company drug hiv infection available low cost case governmental authority indicate pharmaceutical company patent enforceable prevent generic competition major pharmaceutical company greatly reduce price hiv drug certain develop country certain country permit enforcement patent sale viread country reduce generic competition alternatively government country require grant compulsory license allow competitor manufacture sell version viread country reduce viread sale respond governmental concern reduce price viread situation result operation adversely affect manufacturing problem delay product shipment regulatory approval depend party perform manufacture obligation effectively timely basis party fail perform require impair ability deliver product timely basis cause delay clinical trial application regulatory approval event harm competitive position viread hepsera vistide rely party manufacture bulk drug substance final drug product clinical commercial purpose example roche responsible manufacturing tamiflu january roche announce production problem liquid suspension form tamiflu approve treatment child young year old available liquid suspension form tamiflu return market time flu season production issue affect availability tablet form tamiflu adult adolescent year old japan flu season particularly severe roche sublicensee chugai corporation unable meet heighten demand satisfactorily january chugai issue press release attribute failure manufacturing problem problem japan reduce net sale royalty roche base additionally emtricitabine seek qualification abbott european union contract manufacturer bulk drug substance final drug product seek qualification european union second contract manufacturer emtricitabine bulk drug substance abbott recent history violation current good manufacturing practice regulation cite fda work correction fda consent decree fda conduct preapproval inspection abbott new drug application emtricitabine issue form observation abbott december january abbott submit response form observation fda deem abbott response form observation inadequate abbott unable supply initial launch quantity emtricitabine timely manner emtricitabine launch delay manufacture ambisome daunoxome facility san dimas california formulation manufacturing facility san dimas california manufacturing facility ireland perform certain quality control testing labeling packaging use party alternate contract supplier fill freeze dry certain batch product event natural disaster include earthquake equipment failure strike difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome daunoxome meet market need able obtain material necessary manufacture product material utilize operation facility example depend single supplier high quality amphotericin b daunorubicin hcl distearoylphosphatidylcholine high quality cholesterol manufacture liposomal product supplier key component material name new drug application file fda product significant delay occur qualification new supplier require supply supplier interrupt reason unable ship viread ambisome hepsera vistide daunoxome supply product development clinical trial limited experience manufacture exist product need develop additional manufacturing capacity product potential future product potential product development need develop production technology use large scale order conduct clinical trial produce product commercial sale acceptable cost certain able implement development successfully manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation fda current good manufacturing practice extensive regulation govern manufacturing process stability testing recordkeeping quality standard addition manufacturing operation subject routine inspection regulatory agency similar regulation effect countriesour business rise product liability claim cover insurance indemnity agreement testing manufacturing marketing use viread ambisome hepsera tamiflu vistide daunoxome product development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company successful product liability claim require pay substantial amount impair financial condition ability clinically test market product additionally require governmental regulation test product sell patient result test require determine recall product market subsequent testing product recall increase potential exposure product liability claim internal research program effort obtain right new product party yield potential product clinical development long term success depend ability identify internal research program potential product candidate develop new pharmaceutical product obtain new product product candidate license party significant portion research conduct involve new unproven technology research program identify product candidate require substantial technical financial human resource candidate identify research program appear promise route identify potential product candidate fail yield product candidate clinical development number reason include research methodology successful identify potential product candidate potential product candidate study show unduly harmful effect characteristic indicate unlikely effective drug unable develop large scale manufacturing method efficient costeffective capable meeting stringent regulatory standard hold intellectual property right prevent develop make sell certain product unable obtain suitable product candidate product party number reason include unable purchase license compound term allow appropriate return product competitor unwilling assign license product right unable identify suitable product product candidate area expertise product candidate acquire approve regulatory authority problem safety effectiveness unable develop suitable potential product candidate internal research program obtain right new product party future revenue growth suffer use hazardous material chemical viruse radioactive compound expose potential liability research development involve control use hazardous material chemical viruse radioactive compound believe safety procedure handle dispose material comply standard prescribe state federal regulation completely eliminate risk accidental contamination injury material event accident hold liable significant damage fine risk relate triangle acquisition january emtricitabine receive marketing approval single agent prevent delay commercial sale coformulation viread emtricitabine submit application marketing approval emtricitabine treatment hiv infection european union ability obtain marketing approval coformulation viread emtricitabine depend emtricitabine receive marketing approval single agent treatment hiv infection regulatory authority european union country grant marketing approval emtricitabine conclude safe efficacious intended use addition regulatory authority european union require new product sufficient efficacy safety advantage currently market product extensive preclinical toxicity datum authority conclude emtricitabine approvable single agent emtricitabine similar chemical level epivir gsk lamivudine product market treatment hiv infection available datum indicate product comparable safety efficacy profile emtricitabine receive marketing approval single agent unable obtain marketing approval coformulation viread emtricitabine conduct lengthy expensive clinical trial coformulation order obtain approval propose coformulation viread emtricitabine technically possible effective safe approve regulatory authority intend develop commercialize coformulation viread emtricitabine achieve anticipate synergy potential benefit co formulation significant motivation merger triangle depend successfully create obtain marketing approval co formulation viread emtricitabine expect emtricitabine receive marketing approval major requirement obtain marketing approval coformulation viread emtricitabine clinical study show coformulation emtricitabine viread biologically equivalent emtricitabine viread administer separate formulation need chemistry manufacture bioequivalence package show co formulate tablet give exposure viread emtricitabine drug give individually uncertain possible bring coformulation market emtricitabine approve marketing regulatory authority approve require additional clinicaltrial order obtain regulatory approval addition physical combination emtricitabine viread technically feasible costeffective drug coformulate regulatory authority approve coformulation require additional clinical trial grant marketing approval requirement clinical trial delay failure develop commercialize coformulation emtricitabine viread material adverse effect business financial condition result operation successfully integrate triangle operation business adversely affect integrate gilead triangle complex timeconsuming process prior merger gilead triangle operate independently business corporate culture location employee system gilead triangle operate combine organization begin utilize common information communication system operating procedure financial control human resource practice include benefit train professional development program substantial difficulty cost delay involve integration gilead triangle include distract management business combine company potential incompatibility corporate culture potential inability coordinate research development effort successfully cost delay implement common system procedure operate combine company site international site factor increase operating cost lower anticipate financial performance addition combine company lose corporate partner distributor supplier manufacturer employee factor outside control company achieve anticipate synergy potential benefit underlie company reason merger depend successful integration company failure integrate gilead triangle successfully material adverse effect business financial condition result operation unable manufacture emtricitabine successfully reasonable cost potential future result suffer manufactured emtricitabine familiar manufacturing process emtricitabine completion merger triangle responsible making arrangement obtain supply emtricitabine party anticipate commercial launch follow receipt marketing approval european union triangle adequate arrangement supply supply problem party manufacturer emtricitabine sufficient supply emtricitabine meet commercial demand case future result suffer triangle enter agreement abbott abbott agree manufacture emtricitabine bulk drug substance final drug product transfer manufacturing technology emtricitabine party manufacturer rely abbott party manufacture emtricitabine period time seek qualification abbott european union contract manufacturer abbott recent history violation current good manufacturing practice regulation cite fda work correction fda consent decree fda conduct preapproval inspection abbott new drug application emtricitabine issue form observation abbott december january abbott submit response form observation depend abbott perform obligation effectively timely basis fda deem abbott response form observation inadequate abbott unable supply initial launch quantity emtricitabine timely manner time emtricitabine launch impact event harm competitive position new manufacturer emtricitabine approve regulatory authority delay approval rely abbott emtricitabine supply long period currently anticipate cost supply emtricitabine party manufacturer unacceptably high result operation suffer able arrange manufacture emtricitabine low cost manufacture emtricitabine sure emtricitabine manufacturing cost reduce acceptable level profitability depend triangle operation incur loss triangle inception triangle incur loss inception december accumulate deficit approximately million triangle loss result primarily expense associate acquisition development drug candidate general administrative cost triangle generate revenue sale product candidate date expect triangle operation generate significant revenue achieve profitability trading price security subject significant fluctuation trade price common stock volatile volatile future factor announcement fluctuation competitor operating result change prospect market condition biotechnology stock general significant impact future trading price common stock particular trading price common stock biotechnology company include experience extreme price volume fluctuation times unrelated operating performance company stock affect factor cause volatility price security include clinical trial result regulatory development quarterly variation result business product market cycle fluctuation customer requirement availability utilization manufacturing capacity time new product introduction ability develop implement new technology price security affect estimate projection investment community general economic market condition cost operation product market predict individual effect factor price security factor individually aggregate result significant variation price give period time assurance factor adverse effect trading price common stock item property corporate headquarters include principal executive office research facility locate foster city california location lease approximately square foot space proximately locate building lease cover approximately square foot space group building expire december renewal option remain lease expire march september option renew lease additional fiveyear period occupy facility san dimas california location lease approximately square foot space house research development activity manufacture certain administrative function lease expire november fiveyear renewal option addition lease adjacent warehouse facility square foot space use product distribution administrative function lease expire april additional fiveyear extension durham north carolina lease approximately square foot administrative office laboratory space sublease approximately square foot party lease expire september currently negotiation lessor lease term addition lease approximately square foot space sale market regulatory finance information technology human resource operation europe australia include prepaid year lease square foot manufacturing distribution facility ireland lease expiration date believe facility adequate suitable current nearterm future need item legal proceeding reach settlement elan corporation plc successor company liposome company company agree dismiss legal proceeding involve ambisome term initial settlement agreement initial payment elan million agree additional royalty payment base ambisome sale record million accounting charge accrue litigation settlement expense represent net present value future minimum payment require june enter agreement elan terminate remain ambisome payment obligation initial settlement agreement exchange payment elan million november ulehi notify ulehi believe gilead materially breach licensing agreement ulehi concern selex technology identify aptamer thing assign right agreement ulehi consent contest ulehi allegation meet ulehi allegation actively engage negotiation settle disagreement negotiation prove unsuccessful ulehi choose terminate ulehigilead agreement arbitration concern termination likely result unfavorable outcome arbitration rise award monetary damage adverse remedy possibly include conveyance ulehi gilead right obligation ulehi licensing agreement sublicense party legal action arise ordinary course business believe legal action significant impact business item submission matter vote security holder matter submit vote security holder quarter end december ii item market registrant common stock relate stockholder matter common stock trade nasdaq stock market symbol gild follow table set forth period indicate high low intraday sale price share common stock nasdaq stock market price represent quotation dealer adjustment retail markup markdown commission represent price actual transaction high low quarter second quarter quarter fourth quarter quarter second quarter quarter fourth quarter february share common stock outstanding hold approximately stockholder record pay cash dividend common stock inception anticipate pay foreseeable future december issue million convertible senior note december private offer goldman sachs co resold note qualified institutional investor net proceed approximately million follow table provide certain information respect equity compensation plan effect end fiscal year end december share thousand equity compensation plan information number common share number common remain available share weightedaverage issuance equity issue exercise price compensation plan exercise outstanding exclude security outstanding option option warrant reflect warrant right right column plan category b c equity compensation plan approve security holder equity compensation plan approve security holder total include approximately million share issuable gilead employee stock purchase plan note consolidated financial statement item select financial datum gilead sciences inc select consolidated financial datum thousand share datum year end december consolidated statement operation datum total revenue total cost expense income loss operation gain sale oncology asset income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amount common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharebasic share share calculationbasic amount common sharedilute income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharedilute share share calculationdilute december consolidated balance sheet datum cash cash equivalent marketable security work capital total asset longterm obligation convertible debt accumulate deficit total stockholder equity complete sale oncology asset relate technology osi pharmaceuticals inc record nonoperate gain million record nonoperate gain million sale percent interest proligo gilead sell share osi common stock recognize loss sale marketable security million share partial consideration sale oncology asset gilead sciences inc select consolidated financial datum continue thousand share datum prior period restate reflect merger nexstar pharmaceuticals inc july account pool interest gilead adopt statement financial accounting standard nos collectively refer sfas accounting derivative instrument hedge activity quarter change account change accounting principle effective quarter gilead adopt sec staff accounting bulletin sab revenue recognition financial statement change account change accounting principle cash dividend declare pay common stock item management discussion analysis financial condition result operation overview gilead incorporate delaware june biopharmaceutical company focus discovery development commercialization antiviral antibacterial antifungal treat lifethreatene infectious disease multinational company revenue approve product marketing operation country currently market viread tenofovir disoproxil fumarate treatment hiv infection hepsera adefovir dipivoxil treatment chronic hepatitis b infection ambisome amphotericin b liposome injection antifungal agent daunoxome daunorubicin citrate liposome injection drug approve treatment kaposi sarcoma vistide cidofovir injection treatment cmv retinitis roche market tamiflu oseltamivir phosphate treatment influenza collaborative agreement seek add exist portfolio product clinical development program internal discovery program active product acquisition inlicense strategy acquisition triangle complete january internal discovery activity include identification new molecular target target screen medicinal chemistry addition currently develop product treat hiv hbv infection expertise liposomal drug delivery technology use develop drug safe easy patient tolerate effective december complete sale oncology asset osi pharmaceuticals inc transaction value million cash osi stock transaction allow focus continue strengthen core expertise infectious disease note consolidated financial statement information year end december gilead adopt statement financial accounting standard nos collectively refer sfas accounting derivative instrument hedging activity result cumulative effect change accounting principle year end december gilead adopt securities exchange commission staff accounting bulletin revenue recognition financial statement result cumulative effect change accounting principle certain prior period amount reclassify conform current presentation forwardlooke statement risk factor follow discussion contain forwardlooke statement involve risk uncertainty gilead actual result differ materially discuss forwardlooke statement factor cause contribute difference include limited discuss section caption business include risk factor affect gilead forwardlooke statement include document base information currently available gilead include effect acquisition triangle guidance specifically note evaluate detailed financial impact triangle operation consolidate financial statement assume obligation update forwardlooke statement follow discussion read conjunction consolidated financial statement note include report viread sale rely sale viread significant portion operate income number drug treat hiv infection aid currently sell advanced stage clinical development include product currently sell company significant competitor thehivaid market gsk bms roche pfizer merck boehringeringelheim abbott laboratories give broad range competitor depth resource viread market penetration limit particularly use treatmentnave patient give datum support viread approval treatmentexperience patient population ambisome sale rely sale ambisome significant portion operating income lower price product compete ambisome product compete ambisome recently approve european union product develop compete ambisome future antifungal product achieve market acceptance antifungal product development commercially available revenue sale ambisome likely decrease result reduction operating income acquisition integration january complete acquisition triangle acquisition carry inherent risk able successfully integrate triangle operation obtain anticipate synergy cost saving unsuccessful obtain marketing approval emtricitabine develop coformulated product failure successfully integrate triangle operation business obtain marketing approval emtricitabine adversely affect financial position result operation market acceptance product ability product achieve sustain market acceptance depend number factor include receipt scope regulatory approval availability public private insurance reimbursement product safety efficacy tolerability cost product ease administration dose product compare competitive product product achieve sustain market acceptance result operation suffer regulatory process food drug administration foreign agency reject limit commercialization product number reason include disagree result design clinical trial believe product unacceptable efficacy toxicity tolerability believe product manufacture commercial basis compliance applicable safety quality standard agency reject limit commercialization product financial result adversely affect clinical trial require regulatory approval product extremely expensive difficult accurately predict control timing expense quarter quarter addition regulatory agency require conduct additional unanticipated clinical trial product cost substantial governmental legislation reimbursement program regulatory legal legislative issue adversely affect pricing sale product federal legislation lower price product purchase reimburse federal agency state enact legislation low price product addition grow number federal state legislative proposal enact lower price product country outside government sponsor health care program set low drug price patient reimbursement level sale country relatively high price reduce product import country low price market particular concern european union require permit cross border sale concern legislation ease import restriction enact applied international credit risk subject credit risk account receivable relate european product sale european product sale government own support customer greece spain portugal italy subject significant payment delay government funding reimbursement practice significant change occur reimbursement practice european government government funding unavailable financial position result operation adversely affect compulsory licensing generic competition number develop country government official group suggest pharmaceutical company drug hiv infection available low cost case governmental authority indicate pharmaceutical company patent enforceable prevent generic competition major pharmaceutical company greatly reduce price hiv drug certain develop country certain country permit enforcement patent sale viread country reduce generic competition alternatively government country require grant compulsory license allow competitor manufacture sell version viread country reduce viread sale respond governmental concern reduce price viread situation result operation adversely affect collaboration depend collaboration development commercialization certain product revenue include collaboration fujisawa sale ambisome canada collaboration gsk clinical regulatory development commercialization hepsera asia latin america certain territory collaboration roche sale tamiflu worldwide seek additional collaboration collaboration fail number reason include partner devote sufficient resource development commercialization marketing product dispute arise partner exist collaboration fail financial result adversely affect foreign currency fluctuation significant percentage product sale denominate foreign currency increase value dollar foreign currency past reduce future reduce dollar return sale negatively impact financial condition prior january hedge exposure impact fluctuate foreign exchange rate forecast sale effective january begin use forward contract hedge percentage forecast international sale primarily denominate euro currency hedge portion account receivable balance denominate foreign currency minimize eliminate exposure currency fluctuation date sale record date cash collect additionally mitigate impact currency rate fluctuation cash outflow certain foreign currencydenominate raw material purchase enter foreign exchange forward contract hedge foreign currencydenominate account payable uncertain financial result expect financial result continue fluctuate quarter quarter fluctuation substantial fluctuation cause factor control include risk factor list december accumulate deficit million critical accounting policy estimate gilead discussion analysis financial condition result operation base consolidated financial statement prepare accordance accounting principle generally accept united states preparation financial statement require estimate judgment affect report amount asset liability revenue expense relate disclosure asset liability ongoingbasis evaluate estimate include related revenue recognition bad debt inventory accrue clinical preclinical expense contingency base estimate historical experience market specific assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate gilead believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement record estimate reduction revenue expect return expire product medicaid reimbursement customer incentive cash discount prompt payment estimate medicaid reimbursement cash discount base contractual term expectation utilization rate program estimate product return include new product base ongoing analysis industry historical return pattern expect return market drug generally low shelf life product range month viread month ambisome condition competitive market serve drug circumstance change action increase product return estimate offer additional customer incentive result incremental reduction future revenue time return estimate change incentive offer maintain allowance doubtful account estimate loss result inability customer require payment allowance base analysis factor include limited historical payment pattern customer individual customer circumstance analysis day sale outstanding customer geographic region review local economic environment potential impact government funding reimbursement practice financial condition customer economic environment operate deteriorate result inability payment additional allowance require write inventory base quality control review individual raw material batch generally maintain inventory reserve base estimate obsolescence risk competition primarily shelf life product long current assumption future demand competition change actual market condition favorable project management additional inventory reserve require record accrual estimate clinical preclinical study cost cost significant component research development expense management accrue cost clinical study perform contract research organization base estimate generally work upfront cost remain activity occur straightline basis life individual contract study estimate match actual service perform organization determine patient enrollment level relate activity monitor patient enrollment level relate activity extent possible management underestimate activity level associate study give point time record additional research development expense future period significant result operation revenue total revenue million million million include total revenue net product sale royalty income contract revenue include revenue research development rd manufacturing collaboration net product sale revenue million compare million million product sale increase compare primarily significant increase sale viread approve sale october european union february significant percentage gilead product sale continue denominate foreign currency prior hedge exposure impact fluctuate foreign exchange rate forecast sale effective january begin use forward contract hedge percentage forecast international sale reduce eliminate fluctuation sale change foreign currency exchange rate primarily denominate euro currency loss revenue hedge reduce product revenue million sale viread million total product sale compare million total product sale viread sale million sale million international sale continue market expansion viread expect viread sale approximately double range million million sale ambisome million increase ambisome sale million sale ambisome million prior revenue primarily derive sale ambisome represent total product sale total product sale total product sale exclude impact foreign currency relative dollar ambisome sale grow year end december comparable period increase sale compare primarily volume sale increase europe offset decline sale increase sale compare primarily volume price increase europe addition exclude impact decline foreign currency relative dollar sale ambisome increase expect increase competition expect ambisome sale low range million million record royalty revenue million compare million million threeyear period significant source royalty revenue sale ambisome fujisawa copromotion arrangement royalty revenue fujisawa million compare million million record royalty revenue million million million relate sale tamiflu tamiflu orally administer compound develop treat prevent viral influenza human gilead codevelope tamiflu roche own worldwide commercial right tamiflu require pay royalty net sale product begin recognize royalty tamiflu quarter june roche receive european regulatory approval tamiflu treatment influenza adult child prevention adolescent adult difficult toestimate party product sale record royalty revenue quarter arrear total contract revenue million compare million million primary source contract revenue licensing selex process patent estate archemix collectibility concern recognize cash basis provide million contract revenue million roche milestone payment million european prophylaxis treatment approval tamiflu million milestone payment relate development tamiflu rd collaboration agreement contract revenue roche consist million milestone payment relate roche complete regulatory filing approval tamiflu japan december gilead entitle additional milestone payment million roche achieve certain developmental regulatory milestone april gilead gsk enter licensing agreement provide gsk right commercialize hepsera gilead antiviral treatment chronic hepatitis b asia latin america certain territory agreement gilead retain right hepsera canada eastern western europe australia new zealand gsk receive exclusive right develop hepsera solely treatment hepatitis b territory significant include china korea japan taiwan addition gsk pay gilead upfront licensing fee million payment additional obligation pay million achievement gsk certain regulatory development commercial milestone million million receive approval hepsera september gsk pay gilead royalty net sale hepsera gsk territory gsk responsibility development commercialization hepsera gsk territory million upfront fee million approval fee record defer revenue total million recognize contract revenue balance defer revenue december amortize contract revenue period gilead remain obligation agreement approximately year december complete sale oncology asset osi date receive million cash million osi stock agreement entitle additional payment osi million cash combination cash osi stock osi reach certain development milestone nx advanced oncology product candidate sell osi relate manufacturing agreement produce nx gs l liposomal product include sale manufacturing facility san dimas california recognize million contract revenue manufacturing agreement october enter agreement archemix corporation relate selex technology agreement give archemix exclusive right selex process include therapeutic commercial application extent license preexist agreement archemix pay million million require license agreement ulehi pay million million payment ulehi receive warrant purchase share archemix common stock value material require license agreement ulehi transfer warrant ulehi march enter agreement eyetech pharmaceuticals inc relate gilead proprietary aptamer eye currently know macugen currently early clinical trial macugen inhibitor vascular endothelial growth factor vegf know play role development certain ophthalmic disease term agreement eyetech receive worldwide right therapeutic use macugen product successfully commercialize eyetech pay royalty worldwide sale product eyetech responsible research development cost provide clinical supply product eyetech march receive million upfront licensing fee eyetech april recognize revenue ratably oneyear supply agreement period accordingly million license fee record contract revenue million recognize revenue entitle additional cash payment eyetech million eyetech reach certain macugen development milestone additionally receive warrant purchase share eyetech series b convertible prefer stock exercisable price share price stock issue investor gross margin product gross margin compare improvement primarily drive product mix viread high margin product contribute significantly net product sale modest sale viread record foreign exchange impact gross margin price product currency country product sell significant majority manufacturing cost dollar example increase value foreign currency relative dollar positively impact gross margin manufacturing cost remain approximately revenue translate dollar increase gross margin positively impact weaken dollar gross margin negatively impact factor discuss product sale section caption revenue potential impact unpredictable uncontrollable change exchange rate relative dollar mix product sale viread hepsera ambisome expect gross margin remain relatively stable compare operating expense rd expense total cost expense total rd expense million compare million million major component rd expense consist personnel cost include salary benefit clinical study perform contract research organization material supply overhead allocation consist support facility relate cost rd activity separate main category research clinical development pharmaceutical development research cost typically consist preclinical toxicology work clinical development cost include phase clinical trial expand access program pharmaceutical development cost consist product formulation chemical analysis follow table break major component research development spend thousand research clinical development pharmaceutical development oncology divest total million decrease rd spending compare primarily reduction expense associate clinical program viread approve october elimination expense associate oncology program result sale oncology program osi december additionally recognize expense million million upfront license fee pay cubist pharmaceutical relate european licensing agreement daptomycin know cidecin sign january termination agreement september million record rd represent remain unamortized asset relate preclinical oral formulation daptomycin exclude impact triangle acquisition expect rd expense approximately million million approximately high expense million increase rd spending versus attributable recognition million million upfront payment million clinical milestone payment cubist european licensing agreement cidecin addition expense associate clinical program viread hepsera increase approximately million million respectively year recent industry report indicate biopharmaceutical company generally take year average year research develop bring market new prescription medicine average generally consistent project develop internally recent product development timeline accelerate basis drug development process include step define fda process begin file ind successful allow opportunity clinical study potential new medicine clinical development typically involve phase study phase generally account average seven year drug total development time significant cost associate clinical development phase trial tend long large study conduct drug development process currently product development phase study successful development product highly uncertain estimation completion date rd expense vary significantly product difficult predict successful development fda approval product undertake additional study try expand product label market potential complete discussion risk uncertainty associate complete development product risk factor affect gilead section item sell general administrative sga expense million compare million million increase expense compare primarily global sale marketing effort include expansion gilead european sale force support commercial launch viread hepsera increase sga expense versus primarily gilead increase global marketing effort expansion sale force support commercial launch viread expect sga expense exclude impact triangle acquisition approximately million million high level primarily increase marketing activity associate continued promotion viread hepsera ambisome gain sale oncology asset december complete sale oncology asset pipeline clinical stage oncology product relate intellectual property boulder colorado operation include clinical research drug development personnel infrastructure facility osi pipeline clinical candidate include nx liposomal lurtotecan gs nucleoside analogue gs l liposomal thymidylate synthase inhibitor closing date receive million cash osi common stock value approximately million record nonoperating gain million fourth quarter result transaction addition record income taxis million connection transaction loss sale marketable security july company sell remain share osi common stock approximately million share partial consideration sale oncology asset osi december time record fair market value approximately million connection sale remain share recognize nonoperate loss approximately million year end december gain sale unconsolidated affiliate august sell percent interest proligo llc proligo degussa corporation million cash proligo joint venture gilead skw americas inc focus manufacturing oligonucleotide skw americas subsidiary degussa corporation hold remain percent proligo proceed net gilead investment proligo reflect million gain sale unconsolidated affiliate interest income interest expense record interest income million compare million million decrease compare attributable significant decline interest rate partially offset high average cash balance positive cash flow operation proceed sale oncology asset osi increase high average balance invest fund interest income depend principally prevail interest rate control level cash cash equivalent marketable security balance incur interest expense million compare million million significant increase year interest million convertible subordinate note interest expense consist primarily interest million convertible note convert common stock august expect interest expense increase compare expense level primarily issuance million convertible senior note december income taxis provision income taxis million million million respectively income tax expense primarily associate income earn foreign subsidiary significant net operating loss reduce tax liability significant increase income tax expense result principally gain sale oncology asset osi record approximately million federal state alternative minimum taxis provision reduce change income tax law law allow net operating loss carryforward deduction offset alternative minimum taxable income result reduction income tax record previous year million record valuation allowance reduce defer tax asset likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance determine able realize defer tax asset future adjustment defer tax asset increase income period determination likewise determine able realize defer tax asset future adjustment defer tax asset charge income period determination evaluate realizibility defer tax asset quarterly basis equity loss unconsolidated affiliate record million equity loss unconsolidated affiliate proligo prior date sale percent interest record million equity loss proligo represent percent share proligo loss thirteenmonth period end december fourth quarter proligo change fiscal yearend december november cumulative effect change accounting principle year end december gilead adopt sfas accounting derivative instrument hedging activity result cumulative effect change accounting principle million year end december gilead adopt securities exchange commission staff accounting bulletin revenue recognition financial statement result cumulative effect change accounting principle million note consolidated financial statement discussion liquidity capital resource fourth quarter misclassification discover december balance sheet cash flow statement year end december million osi stock receive consideration divestiture oncology asset misclassifie balance sheet cash cash equivalent instead marketable security misclassification impact statement operation period include revenue net income december consolidated balance sheet consolidate statement cash flow report change reflect correct classification cash cash equivalent marketable security total million december million december increase million primarily million net proceed receive issuance convertible senior note december major source use cash include net cash provide operation million proceed issuance stock employee stock plan million partially offset capital expenditure million million convertible note receive triangle million loan triangle return connection complete acquisition january approximately million pay complete acquisition triangle work capital december million compare million december significant change working capital include million increase account receivable million increase inventory account receivable increase primarily increase sale viread europe million increase inventory primarily increase production viread inventory meet increase sale demand significant change current liability include million increase accrue liability million decrease accrue clinical preclinical expense million increase accrue compensation million increase account payable million increase defer revenue million increase accrue liability primarily medicaid rebate obligation associate high sale viread million decrease accrue clinical preclinical expense primarily decrease activity associate clinical trial program viread hepsera million increase accrue compensation primarily increase bonus accrual expansion sale force million increase account payable primarily increase raw material purchase support viread sale growth million increase defer revenue primarily relate million receive collaboration gsk enter april million effect exchange rate change cash primarily weaken dollar relative euro translation foreign subsidiary account receivable balance primarily denominate euro currency capital expenditure million million million expenditure primarily facility improvement accommodate growth laboratory manufacturing equipment capital expenditure relate research development million spend million spend expect capital spending significantly high level increase infrastructure need high rd spending december issue million convertible senior note december private offering note currently convertible total share gilead common stock share conversion price high gilead common stock price note issuance date note redeemable option time june specify redemption price plus accrued interest debt issuance cost million incur connection issuance note record noncurrent asset amortize interest expense straightline basis contractual term note december issue million convertible subordinated note december private offering note currently convertible total share gilead common stock share conversion price high gilead common stock price note issuance date note redeemable option time december specify redemption price plus accrued interest debt issuance cost million incur connection issuance note record noncurrent asset amortize interest expense straightline basis contractual term notesin august redeem convertible subordinated debenture cash price principal debenture outstanding plus accrued interest redemption price provide original debenture indenture redemption entire million principal debenture outstanding time convert newly issue share gilead common stock august defer debt issuance cost million relate debenture charge additional pay capital connection conversion debenture common stock believe exist capital resource supplement cash generate operation adequate satisfy capital need foreseeable future future capital requirement depend factor include commercial performance viread hepsera ambisome commercial performance product development receive marketing approval include emtricitabine acquisition triangle complete january success partner research development commercialization effort product partner progress research development effort scope result preclinical study clinical trial cost timing outcome regulatory review rate technological advance determination commercial potential product development administrative expense status competitive product establishment manufacturing capacity thirdparty manufacturing arrangement expansion sale marketing capability possible geographic expansion establishment additional collaborative relationship company future require additional funding form proceed equity debt financing additional collaborative agreement corporate partner fund require assure available favorable term subsidiary establish variety subsidiary country purpose conduct business location subsidiary consolidate financial statement special purpose entity unconsolidate financial statement include define variable interest entity financial accounting standard board fasb interpretation consolidation variable interest entity involve nonexchange trade commodity contract account fair value commercial commitment relate party employee loan contractual obligation form capital operating lease note payable clinical research organization contract recent accounting pronouncement june fasb issue sfas accounting cost associate exit disposal activity sfas require liability cost associate exit disposal activity recognize measure initially fair value liability incur sfas effective exit disposal activity initiate december adoption sfas expect material impact financial position result operation november eitf reach consensus issue address account arrangement involve delivery performance multiple product service andor right use asset revenue arrangement multiple deliverable divide separate unit account deliverable arrangement meet follow criterion deliver item value customer standalone basis objective reliable evidence fair value undelivere item delivery undelivered item probable arrangement consideration allocate separate unit account base relative fair value allocate deliver item limit contingent delivery additional item meeting specify performance condition final consensus applicable agreement enter fiscal period begin june early adoption permit review provision consensus determine effect company financial position result operation november fasb issue interpretation fin guarantor accounting disclosure requirement guarantee include indirect guarantee indebtedness fin elaborate exist disclosure requirement guarantee include residual value guarantee issue conjunction operate lease agreement clarify time company issue guarantee company recognize initial liability fair value obligation assume guarantee disclose information interim annual financial statement initial recognition measurement provision apply prospective basis guarantee issue modify december disclosure requirement effective financial statement interim annual period end december adoption disclosure provision fin material impact result operation financial position december fasb issue sfas accounting stockbase compensationtransition disclosure sfas amendment sfas accounting stockbase compensation issue october sfas provide alternative method transition voluntary change fair value base method accounting stockbase compensation addition statement amend disclosure requirement statement require prominent disclosure annual interim financial statement method accounting stockbase employee compensation effect method report result additional disclosure requirement sfas effective fiscal year end december elect continue follow intrinsic value method accounting prescribe accounting principle board opinion apb accounting stock issue employee account employee stock option item quantitative qualitative disclosure market risk foreign currency exchange risk operation include manufacture sale activity sale activity europe australia result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change exchange rate dollar foreign currency significant euro british pound australian dollar dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business mitigate impact change currency exchange rate cash flow foreign currency sale transaction enter foreign exchange forward contract hedge foreign currencydenominate account receivable additionally mitigate impact currency rate fluctuation cash outflow certain foreign currencydenominate raw material purchase enter foreign exchange forward contract hedge foreign currencydenominate account payable significant percentage product sale denominate foreign currency increase value dollar foreign currency past reduce future reduce dollar return sale negatively impact financial condition prior hedge exposure impact fluctuate foreign exchange rate forecast sale effective january begin use forward contract hedge percentage forecast international sale primarily denominate euro currency follow table summarize notional amount average currency exchange rate fair value open foreign exchange forward contract december contract maturity year exception hedge contract intend hedge raw material purchase quarter notional million insignificant fair value december maturity month average rate state term foreign currency dollar fair value represent estimate settlement amount december notional amount fair value dollar thousand fair value currency notional average rate december british pound euro total notional million fair value million open foreign exchange forward contract december compare total notional million fair value million open foreign exchange forward contract december interest rate risk portfolio availableforsale investment security fixedrate liability create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base duration industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return follow table summarize expect maturity average interest rate interestbeare asset fixedrate liability december dollar thousand year end december fair value december total asset availableforsale security average interest rate liability longterm obligation include current portion average interest rate convertible senior debenture interest rate convertible subordinated debenture interest rate longterm obligation consist capital lease operating lease net noncancelable sublease debt secure property plant equipment interest portion payment include international credit risk account receivable balance december million compare million december growth primarily high product sale viread europe certain country payment typically slow primarily greece spain portugal italy account receivable balance significant case slow payment practice reflect pace governmental entity reimburse customer turn increase financial risk relate certain customer sale customer country tend relatively slow pay past increase future increase average length time account receivable outstanding december past account receivable greece spain portugal italy total approximately million approximately million day past december past receivables country million approximately million day past date experience significant loss respect collection account receivable believe account receivable balance reflect consolidated balance sheet include customer country collectible continually seek improve collection process ensure fully collect amount base product sale collection timely item financial statement supplementary datum financial statement require item set forth begin report incorporate reference item change disagreement accountant account financial disclosure applicable iii item director executive officer registrant information require item concern director executive officer incorporate reference section definitive proxy statement file sec pursuant regulation connection annual meeting proxy statement heading nominee executive officer compliance section security exchange act item executive compensation information require item incorporate reference section proxy statement heading executive compensation compensation committee report item security ownership certain beneficial owner management information require item incorporate reference section proxy statement head security ownership certain beneficial owner management item certain relationship relate transaction information require item incorporate reference section proxy statement heading compensation committee interlock insider participation certain transaction executive compensation item control procedure day prior date report carry evaluation supervision participation principal executive officer andprincipal financial officer effectiveness design operation disclosure control procedure base evaluation principal executive officer principal financial officer conclude disclosure control procedure effective timely alert material information require include periodic report security exchange commission note design system control base certain assumption likelihood future event certain design succeed achieve state goal potential future condition regardless remote significant change internal control factor significantly affect control subsequent date evaluation iv item exhibit financial statement schedule report form k follow document file index list financial statement report ernst young llp independent auditor report independent accountant audit consolidated financial statement consolidate balance sheet consolidate statement operation consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement schedule ii include report schedule omit require require information include financial statement note thereto exhibit follow exhibit file herewith incorporate reference exhibit exhibit footnote number description document asset purchase agreement registrant osi pharmaceuticals inc date november agreement plan merger registrant simbolo acquisition sub inc whollyowne subsidiary registrant triangle pharmaceutical inc date december amend restate certificate incorporation registrant amend bylaw registrant amend restate march reference exhibit exhibit amend restate right agreement date october registrant chasemellon shareholder services llc agreement plan merger date february registrant gazelle acquisition sub inc nexstar pharmaceuticals inc indenture date december registrant chase manhattan bank trust company national association include form note indenture date december registrant jp morgan trust company national association include form note registration right agreement date december registrant goldman sachs co form indemnity agreement enter registrant director executive officer form employee proprietary information invention agreement enter registrant certain officer key employee registrant incentive stock option plan relate agreement registrant supplemental stock option plan relate agreement registrant employee stock purchase plan amend march registrant stock option plan amend restate april amend january amend january form nonqualified stock option issue certain executive officer director vintage park research development net lease registrant vintage park associate date march premise locate b lakeside drive foster city california relate addendum exhibit amendment letter agreement date september registrant iocbrega exhibit certain confidential information omit vintage park research development net lease registrant vintage park associate date september premise locate lakeside drive foster city california related exhibit amendment agreement date october registrant iocbrega relate license agreement exhibit certain confidential information omit amendment agreement date december registrant iocbrega loan agreement date october registrant mark l perry melanie p pea registrant nonemployee director stock option plan amend january amend january vintage park research development lease registrant wcb sixteen limited partnership date june premise locate lakeside drive foster city california amendment vintage park research development lease registrant wcb seventeen limit partnership date june premise locate lakeside drive foster city california amendment vintage park research development lease registrant wcb seventeen limit partnership date june premise locate b lakeside drive foster city california license supply agreement registrant pharmacia upjohn sa date august certain confidential information omit development license agreement registrant f hoffmannla roche ltd hoffmannla roche inc date september certain confidential information omit amendment vintage park research development lease registrant spieker property lp date august premise locate lakeside drive foster city california nexstar pharmaceuticals inc incentive stock plan adopt february amend nexstar pharmaceuticals inc director option plan adopt july vestar inc stock option plan lease date march vestar inc majestic realty co patrician associates inc amendment thereto amendment thereto date june amendment date january majestic realty co patrician associates inc registrant lease date march vestar inc majestic realty co patrician associates inc assignment royalty agreement date december effective june vestar inc city hope national medical center license agreement effective august vestar inc regents university california agreement fujisawa usa inc vestar inc date august amendment thereto date amendment agreement fujisawa usa inc vestar inc date april fujisawa usa inc vestar inc certain confidential information omit amendment agreement fujisawa usa inc registrant date march agreement fujisawa usa inc vestar inc date august lease date april vestar inc majestic realty co patrician associates inc amendment lease date april majestic realty co patrician associates inc vestar inc amend lease date april majestic realty co patrician associates inc vestar inc license distribution agreement date september sumitomo pharmaceutical co ltd nexstar pharmaceuticals inc certain confidential information omit settlement agreement date august nexstar pharmaceuticals inc fujisawa usa inc liposome company inc certain confidential information omit amendment date april sumitomo pharmaceutical co ltd nexstar pharmaceuticals inc license distribution agreement date september sumitomo nexstar pharmaceuticals inc corporate plan retirement select planbasic plan document corporate plan retirement select planadoption agreement addendum gilead sciences inc defer compensation plan licensing agreement date april gilead world market limited glaxo group limited employment agreement date july gilead sciences inc sharon surreybarbari triangle pharmaceuticals inc stock incentive plan option agreement triangle pharmaceuticals inc daniel g welch date august license agreement triangle pharmaceuticals inc emory university university georgia research foundation inc compound amdoxovir dapd date march license agreement triangle pharmaceuticals inc emory university coviracil ftc date april license agreement triangle pharmaceuticals inc bukwang pharm ind co ltd date february exclusive license agreement triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university date settlement agreement triangle pharmaceuticals inc emory university dr david w barry glaxo wellcome plc glaxo wellcome inc glaxo group limited wellcome foundation limited date amendment license agreement triangle pharmaceuticals inc bukwang pharm ind co ltd date april amendment license agreement triangle pharmaceuticals inc emory university date amendment license agreement triangle pharmaceuticals inc emory university university georgia research foundation inc date july second amendment license agreement triangle pharmaceuticals inc emory university date july amendment license agreement triangle pharmaceuticals inc bukwang pharm ind co ltd date september amendment license agreement triangle pharmaceuticals inc bukwang pharm co ltd date august supply manufacturing agreement triangle pharmaceuticals inc abbott laboratories date july settlement exclusive license agreement triangle pharmaceuticals inc shire biochem inc shire pharmaceuticals group plc emory university university georgia research foundation date august second amendment license agreement triangle pharmaceuticals inc emory university university georgia research foundation inc date august sublease triangle pharmaceuticals inc eli lilly company date january sublease amendment triangle pharmaceuticals inc eli lilly company date march second amendment sublease triangle pharmaceuticals inc eli lilly company date august amendment sublease triangle pharmaceuticals inc eli lilly company date february manufacture supply agreement gilead world markets ltd ppgsipsy sas enter january subsidiary registrant consent ernst young llp independent auditor consent pricewaterhousecooper llp independent auditor power attorney reference signature certification file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form q quarter end december incorporate reference file exhibit nexstar pharmaceuticals inc quarterly report form q quarter end june incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant registration statement form amend incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant annual report fiscal year end march incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant current report form k file march incorporate reference file exhibit nexstar pharmaceuticals inc fiscal year end december incorporate reference file exhibit nexstar pharmaceuticals inc fiscal year end december incorporate reference file exhibit nexstar pharmaceuticals inc form q quarterly period end september incorporate reference file exhibit nexstar pharmaceuticals inc fiscal year end december incorporate reference file march exhibit nexstar pharmaceuticals inc registration statement form file incorporate reference file exhibit nexstar pharmaceuticals inc form q quarterly period end september incorporate reference file exhibit nexstar pharmaceuticals inc form q quarter end june incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant registration statement form amend incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant current report form k file january incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant current report form k file december incorporate reference file exhibit registrant registration statement form file january incorporate reference file exhibit registrant registration statement form file january incorporate reference file exhibit triangle pharmaceuticals inc registration statement form amend incorporate reference file exhibit triangle pharmaceuticals inc fiscal year end december incorporate reference file exhibit triangle pharmaceuticals inc quarterly report form q quarter end september incorporate reference file exhibit triangle pharmaceuticals inc quarterly report form q quarter end september incorporate reference file exhibit triangle pharmaceuticals inc current report form k file september incorporate referencefile exhibit triangle pharmaceuticals inc current report form k file september incorporate reference file exhibit triangle pharmaceuticals inc quarterly report form q quarter end september incorporate reference file exhibit triangle pharmaceuticals inc fiscal year end december incorporate reference certain confidential portion exhibit omit mean mark portion asterisk mark exhibit file separately secretary sec mark pursuant registrant application request confidential treatment rule b securities exchange act b report form k registrant file report form k december tender offer purchase outstanding common share triangle pharmaceuticals inc price share registrant file report form k december december sale million convertible note million overallotment exercise rule offer qualified institutional buyer gilead sciences inc consolidated financial statement year end december content report ernst young llp independent auditor report independent accountant audit consolidated financial statement consolidate balance sheet consolidate statement operation consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement report ernst young llp independent auditor board director stockholder gilead sciences inc audit accompany consolidated balance sheet gilead sciences inc december relate consolidated statement operation stockholder equity cash flow year period end december audits include financial statement schedule list item annual report financial statement schedule responsibility management gilead sciences inc responsibility express opinion financial statement schedule base audits audit financial statement proligo llc limited liability company investment reflect accompany consolidated financial statement equity method accounting company equity net loss proligo llc financial statement proligo llc audit auditor report furnish opinion insofar relate amount include proligo llc base solely report auditor conduct audits accordance auditing standard generally accept united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits report auditor provide reasonable basis opinion opinion base audits report auditor consolidated financial statement refer present fairly material respect consolidate financial position gilead sciences inc december consolidate result operation cash flow year period end december conformity accounting principle generally accept united states opinion financial statement schedule refer consider relation basic financial statement take present fairly material respect information set forth discuss note consolidated financial statement effective january company change method accounting derivative instrument hedge activity effective january change method accounting nonrefundable upfront fee receive connection collaboration agreement ernst young llp palo alto californiajanuary report independent accountant board director member proligo llc opinion accompany consolidated balance sheet relate consolidated statement operation member equity cash flow present fairly material respect financial position proligo llc subsidiary december november result operation cash flow thirteenmonth end december year end november period august november respectively conformity accounting principle generally accept united states america financial statements responsibility company management responsibility express opinion financial statement base audit conduct audits statement accordance auditing standard generally accept united states america require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion pricewaterhousecooper llp broomfield colorado january gilead sciences inc consolidated balance sheet thousand share amount december asset current asset cash cash equivalent marketable security accounts receivable net allowance doubtful account december december note receivable triangle pharmaceutical inc inventory prepaid expense total current asset property plant equipment net noncurrent asset liabilitie stockholder equity current liability account payable accrue clinical preclinical expense accrue compensation employee benefit accrue liability defer revenue longterm obligation year total current liability longterm defer revenue accrue litigation settlement expense year longterm obligation year convertible senior debt convertible subordinated debt commitment contingency accompany note stockholder equity prefer stock par value share issuable series share authorize outstanding common stock par value share share authorize share issue outstanding december december respectively additional paidin capital accumulate comprehensive income accumulate deficit total stockholder equity accompany note gilead sciences inc consolidated statement operation thousand share amount year end december revenue product sale royalty revenue contract revenue total revenue cost expense cost good sell research development sell general administrative total cost expense income loss operation gain sale oncology asset gain sale unconsolidated affiliate loss sale marketable security interest income net interest expense income loss provision income taxis equity loss unconsolidated affiliate cumulative effect change accounting principle provision income taxis equity loss unconsolidated affiliate income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amount common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharebasic share share calculationbasic amount common sharedilute income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharedilute share share calculationdilute accompany note gilead science incconsolidate statement stockholder equity thousand common stock accumulate additional pay comprehensive income total stockholder share capital loss defer compensation accumulate deficit equity balance december net loss unrealize gain availableforsale security net foreign currency translation adjustment comprehensive loss employee stock purchase plan option exercise net warrant exercise net conversion convertible subordinated debenture amortization defer compensation compensatory stock transaction balance december net income unrealize gain availableforsale security net foreign currency translation adjustment unrealize gain cash flow hedge net comprehensive income employee stock purchase plan option exercise net tax benefit employee stock plan amortization defer compensation compensatory stock transaction balance december net income unrealize loss availableforsale security net foreign currency translation adjustment unrealize gain cash flow hedge net comprehensive income employee stock purchase plan option exercise net tax benefit employee stock plan compensatory stock transaction balance december accompany note gilead sciences inc consolidated statement cash flow thousands year end december operating activity net income loss adjustment reconcile net income loss net cash provide operating activity depreciation amortization net effect change accounting principle gain sale oncology asset gain sale unconsolidated affiliate loss sale marketable security equity loss unconsolidated affiliate net movement provision doubtful account tax benefit employee stock plan net unrealized gain loss foreign currency transaction noncash transaction change operate asset liability account receivable inventory prepaid expense asset longterm prepay royalty account payable accrue liability defer revenue net cash provide operating activity invest activity purchase marketable security sale marketable security maturity marketable security capital expenditure issuance note triangle pharmaceuticals inc proceed sale oncology asset proceed sale unconsolidated affiliate investment unconsolidated affiliate net cash provide investing activity financing activity proceed issuance common stock repayment longterm obligation proceed issuance convertible senior note net issuance cost proceed issuance convertible subordinate note net issuance cost net cash provide financing activity effect exchange rate change cash net increase decrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year supplemental disclosure cash flow information interest pay income taxis pay noncash investing financing activity osi common stock receive sale oncology asset common stock issue conversion debenture reclassification defer debt issuance cost additional paidin capital conversion subordinate debenture accompany note gilead sciences inc note consolidated financial statement december organization summary significant accounting policy overview gilead company incorporate delaware june biopharmaceutical company focus discovery development commercialization antiviral antibacterial antifungal treat lifethreatene infectious disease multinational company revenue approve product operation country currently market viread treatment hiv infection hepsera treatment chronic hepatitis b infection ambisome antifungal agent daunoxome drug approve treatment kaposi sarcoma vistide treatment cmv retinitis roche market tamiflu treatment influenza collaborative agreement seek add exist portfolio product ourclinical development program internal discovery program active product acquisition inlicense strategy acquisition triangle pharmaceuticals inc complete january internal discovery activity include identification new molecular target target screen medicinal chemistry addition currently develop product treat hiv infection expertise liposomal drug delivery technology use develop drug safe easy patient tolerate effective accompany consolidated financial statement include account gilead wholly majorityowne subsidiary significant intercompany transaction eliminate certain prior period amount include certain cash cash equivalent marketable security reclassify consistent current presentation stock split february march gilead complete twoforone stock split effect form stock dividend stockholder record february february respectively accordingly share share amount period present reflect split change accounting principle gilead adopt statement financial accounting standard sfas nos collectively refer sfas accounting derivative instrument hedge activity quarter change account change accounting principle note effective quarter gilead adopt sec staff accounting bulletin sab revenue recognition financial statement change account change accounting principle note critical accounting policy estimate preparation financial statement require estimate judgment affect report amount asset liability revenue expense relate disclosure asset liability ongoing basis management evaluate estimate include related revenue recognition bad debt inventory accrue clinical preclinical expense contingency base estimate historical experience market specific assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate revenue recognition recognize revenue product sale persuasive evidence arrangement exist delivery occur price fix determinable collectibility reasonably assure provide customer general right product return accept return product expire deem damage defective deliver provision estimate product return cash discount government discount rebate base contractual term expectation utilization rate program contract revenue research development record earn base performance requirement contract nonrefundable contract fee performance obligation exist continue involvement gilead recognize early payment receive collection assure revenue nonrefundable upfront license fee milestone payment continue involvement development collaboration obligation supply product recognize manufacturing obligation fulfil ratably development period period manufacturing obligation appropriate revenue associate substantive performance milestone recognize base achievement milestone define respective agreement revenue research development cost reimbursement contract recognize related cost incur advance payment receive excess amount earn classified defer revenue royalty revenue sale ambisome recognize month follow correspond sale occur royalty revenue sale vistide tamiflu recognize receive quarter follow quarter correspond sale occur shipping handle cost shipping handling cost incur inventory purchase product shipment record cost good sell consolidated statement operation research development expense major component rd expense consist personnel cost include salary benefit clinical study perform contract research organization material supply overhead allocation consist administrative facility relate cost research development activity separate main category research clinical development pharmaceutical development research cost typically consist preclinical toxicology work clinical development cost include phase clinical trial expand access program pharmaceutical development cost consist product formulation chemical analysis record accrual estimate clinical preclinical study cost cost significant component rd expense management accrue cost clinical study perform contract research organization base estimate typically work upfront cost remain activity generally incur straightline basis life individual contract study estimate match actual service perform organization determine patient enrollment level relate activity monitor patient enrollment level relate activity extent possible adjust estimate line actual activity incur ongoing basisadvertising expense expense cost advertising include promotional expense incur advertising expense million million million stockbase compensation accordance provision sfas accounting stockbase compensation company elect continue follow accounting principle board opinion apb accounting stock issue employee interpretation fin account certain transaction involve stock compensationan interpretation apb opinion accounting employee stock option plan apb exercise price gilead employee director stock option equal exceed fair value underlie stock date grant compensation expense recognize note pro forma disclosure stockbase compensation pursuant sfas amend sfas accounting stockbase compensation transition disclosure table present combine net income loss basic diluted net income loss common share compensation cost gilead nexstar stock option plan espp determine base estimate fair value award plan grant purchase date thousand share amount year end december net income lossa report deduct total stockbase employee compensation expense determine fair value base method award net relate tax effect pro forma net income loss thousand earning loss share basica report basicpro forma diluteda report dilutedpro forma fair value award grant stock option plan espp estimate grant purchase date blackschole option pricing model multiple option approach follow assumption year end december expect life year vest date stock option espp discount rate stock option espp volatility expect dividend yield weight average estimate fair value espp share purchase share computation basic net income common share compute base weighted average number common share outstanding period dilute net income common share include effect approximately million stock option include effect million convertible note convert approximately million share million convertible note convert approximately million share effect assume conversion antidilutive diluted net income common share include effect approximately million stock option warrant include effect million convertible note convert approximately million share effect assume conversion antidilutive basic diluted loss common share compute base weighted average number common share outstanding period potential common share convertible note stock option warrant convertible debenture previously outstanding exclude computation dilute loss share effect antidilutive cash cash equivalent consider highly liquid investment insignificant interest rate risk remain maturity month purchase date cash equivalent enter overnight repurchase agreement purchase security obligation resell follow day security purchase agreement resell record face value report cash cash equivalent investment policy enter repurchase agreement repos major bank authorize dealer provide repos collateralize government security fair value fair value security sell gilead fourth quarter misclassification discover previously report december balance sheet cash flow statement atdecember million osi stock receive consideration divestiture oncology asset misclassifie balance sheet cash cash equivalent instead marketable security december consolidated balance sheet consolidate statement cash flow report change reflect correct classification marketable security management determine appropriate classification marketable security consist solely debt security time purchase reevaluate designation balance sheet date marketable security classify availableforsale carry estimate fair value report cash equivalent marketable security december cash cash equivalent include million security designate availableforsale million december unrealize gain loss availableforsale security exclude earning report separate component stockholder equity interest income include interest dividend amortization purchase premium discount realize gain loss sale security cost security sell base specific identification method regularly review investment otherthan temporary decline fair value determine decline fair value investment accounting basis otherthantemporary reduce carry value security hold record loss decline reduction require past year concentration credit risk gilead subject credit risk portfolio cash equivalent marketable security policy limit amount invest security duration industry group investment type issuer security issue government gilead expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return gilead subject credit risk account receivable relate product sale significant trade account receivable arise sale ambisome viread primarily sale european subsidiary export sale distributor europe certain country payment typically slow primarily greece spain portugal italy account receivable balance significant case slow payment practice reflect pace governmental entity reimburse customer turn increase financial risk relate certain customer sale customer country tend relatively slow pay past increase future increase average length time account receivable outstanding december past account receivable greece spain portugal italy total approximately million approximately million day past december past receivables country million approximately million day past date experience significant loss respect collection account receivable believe past account receivable reflect consolidated balance sheet include customer country collectible perform credit evaluation customer financial condition generally require collateral material utilize operation facility example depend single supplier high quality amphotericin b daunorubicin hcl distearoylphosphatidylcholine high quality cholesterol manufacture liposomal product supply supplier interrupt reason unable ship viread ambisome hepsera vistide daunoxome supply product development clinical trial december million note receivable triangle pharmaceuticals inc incur conjunction acquisition complete january note include cash cash equivalent marketable security subsequently eliminate consolidation result closing acquisition january inventory inventory record low cost market cost determine firstin firstout basis management periodically review composition inventory order identify obsolete slowmoving unsaleable item item observe alternate use inventory record writedown net realizable value period unit identify impair historically inventory writedown insignificant consistent management expectation property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straight line method estimate useful life follow description estimate useful life year build leasehold improvement laboratory manufacturing equipment office computer equipment office computer equipment include capitalize computer software capitalize software purchase internally develop computer software leasehold improvement capitalize lease equipment amortize short lease term item useful life capitalize interest construction progress include property plant equipment noncurrent asset noncurrent asset december include million respectively prepay royalty pay institute organic chemistry biochemistry academy sciences czech republic rega stichte iocbrega discuss iocbrega caption note include noncurrent asset december net defer debt issuance cost million million respectively relate million convertible senior note issue indecember million subordinate convertible note gilead issue december longlive asset carry value longlive asset review regular basis existence fact circumstance internally externally suggest impairment specific potential indicator impairment include significant decrease fair value asset significant change extent manner asset significant physical change asset significant adverse change legal factor business climate affect value asset adverse action assessment food drug administration regulator accumulation cost significantly excess originally expect acquire construct asset operate cash flow loss combine history operate cash flow loss projection forecast demonstrate continue loss associate incomeproduce asset indication impairment confirm compare estimate future cash flow expect result use asset eventual disposition carry asset estimate future cash flow asset group low level identifiable cash flow largely independent cash flow generate asset group sum expect future cash flow undiscounte interest change carrying asset impairment loss measure excess carrying value asset fair value recognize cash flow estimate calculation base management good estimate appropriate customary assumption projection time foreign currency translation transaction contract adjustment result translate financial statement foreign subsidiary dollar exclude determination net income accumulate separate component stockholder equity net foreign exchange transaction gain loss report sell general administrative expense consolidated statement operation realize gain loss million million million hedge certain foreign currency exposure related outstanding trade account receivable firmly commit purchase transaction forecast product sale foreign exchange forward contract general contract expose market risk gain loss contract offset gain loss transaction hedge exposure credit risk contract function change interest currency exchange rate vary time gilead limit risk counterpartie contract unable perform transact major bank limit risk loss enter contract provide net settlement maturity overall risk loss event counterparty default limit unrecognize unrealized gain outstanding contract ie contract positive fair value date default enter speculative foreign currency transaction write option presently hedge net investment foreign subsidiary accounting hedge account receivable record change fair value sell general administrative expense derivative instrument designate hedge fas selectively hedge anticipate currency exposure purchase forward contract hedge firmly commit purchase transaction anticipate product sale designate cash flow hedge sfas unrealized gain loss underlie forward contract record comprehensive income recognize earning forecast transaction occur december december net unrealized loss open foreign exchange forward contract million million respectively loss revenue hedge reduce product revenue million notional amount forward exchange contract outstanding million december million december contract maturity year exception hedge contract intend hedge raw material purchase quarter notional million insignificant fair value december maturity month note discussion derivative financial instrument adoption sfas fair value financial instrument company financial instrument consist principally cash cash equivalent marketable security accounts receivable certain noncurrent asset forward foreign exchange contract account payable longterm obligation convertible note cash cash equivalent marketable security forward foreign exchange contract hedge account receivable report respective fair value balance sheet forward foreign exchange contract hedge firmly commit purchase record fair value net relate deferred gain loss result report net balance zero fair value convertible senior note december million carrying value december million fair value convertible subordinate note december million fair value december million carrying value end period million fair value december december convertible note determine obtain quote market maker note management believe remain financial instrument report balance sheet amount approximate current fair value recent accounting pronouncementsin june fasb issue sfas accounting cost associate exit disposal activity sfas require liability cost associate exit disposal activity recognize measure initially fair value liability incur sfas effective exit disposal activity initiate december adoption sfas expect material impact financial position result operation november eitf reach consensus issue address account arrangement involve delivery performance multiple product service andor right use asset revenue arrangement multiple deliverable divide separate unit account deliverable arrangement meet follow criterion deliver item value customer standalone basis objective reliable evidence fair value undelivere item delivery undelivered item probable arrangement consideration allocate separate unit account base relative fair value allocate deliver item limit contingent delivery additional item meeting specify performance condition final consensus applicable agreement enter fiscal period begin june early adoption permit review provision consensus determine effect company financial position result operation november fasb issue interpretation fin guarantor accounting disclosure requirement guarantee include indirect guarantee indebtedness fin elaborate exist disclosure requirement guarantee include residual value guarantee issue conjunction operate lease agreement clarify time company issue guarantee company recognize initial liability fair value obligation assume guarantee disclose information interim annual financial statement initial recognition measurement provision apply prospective basis guarantee issue modify december disclosure requirement effective financial statement interim annual period end december adoption disclosure provision fin material impact result operation financial position december fasb issue sfas accounting stockbase compensationtransition disclosure sfas amendment sfas accounting stockbase compensation issue october sfas provide alternative method transition voluntary change fair value base method accounting stockbase compensation addition statement amend disclosure requirement statement require prominent disclosure annual interim financial statement method accounting stockbase employee compensation effect method report result additional disclosure requirement fas effective fiscal year end december elect continue follow intrinsic value method accounting prescribe accounting principle board opinion apb accounting stock issue employee account employee stock option cumulative effect change accounting principle december securities exchange commission issue staff accounting bulletin sab revenue recognition financial statement thing sab describe sec staff position recognition certain nonrefundable upfront fee receive connection collaboration agreement previously recognize nonrefundable technology access fee receive connection collaboration agreement revenue receive collectibility probable technology transfer effective january gilead change method accounting fee recognize related manufacturing obligation fulfil straightline basis term relate research development collaboration manufacturing supply arrangement appropriate method good match effort provide management believe change accounting principle preferable base guidance provide sab cumulative effect change accounting principle record fourth quarter retroactively effective january defer revenue recognize contract revenue remain term research development manufacturing supply arrangement appropriate year end december net impact change accounting principle increase net loss million share loss consist million cumulative effect change january net million relate defer revenue recognize contract revenue year additional million contract revenue recognize remainder million relate deferred revenue balance december expect recognize revenue derivative financial instrument january gilead adopt sfas standard require gilead recognize derivative asset liability measure fair value company enter foreign currency forward contract hedge change fair value monetary asset liability denominate nonfunctional currency derivative designate meet definition fair value hedge change fair value derivative hedge item attributable hedge risk recognize earning company enter foreign currency forward contract generally maturitie month hedge future cash flow related purchase transaction forecast product sale foreign denominate currency derivative instrument employ eliminate minimize certain foreign currency exposure confidently identify quantify accordance sfas hedge relate anticipate foreign currency purchase raw material forecast product sale designate document inception respective hedge designate cash flow hedge evaluate effectiveness quarterly term forward contract underlie transaction match inception forward contract effectiveness calculate compare fair value contract change forward value underlie hedged item adoption sfas record fair value million relate forward contract previously reflect balance sheet recognize cumulative transition adjustment comprehensive income million effective component hedge substantially value report comprehensive income december reclassify earning month residual change fair value instrument ineffectiveness recognize immediately sell general administrative expense ineffectiveness significant gilead hold warrant purchase stock nonpublic company warrant net exercise feature sfas classify derivative instrument adoption gilead record fair value warrant million offset adjustment cumulative change accounting principle million loss hedge contract recognize income statement million increase fair value derivative recognize comprehensive income december fair value derivative include comprehensive income material sale oncology asset december gilead complete sale oncology asset pipeline clinical candidate oncology relate intellectual property boulder colorado operation include clinical research drug development operation infrastructure facility osi clinical development candidate sell osi nx liposomal lurtotecan gs nucleoside analogue gs l liposomal thymidylate synthase inhibitor consideration gilead receive million cash share osi common stock value approximately million december number share issue gilead determine divide million average closing sale price osi common stock day precede december entitle additional payment osi million cash combination cash osi common stock osi reach certain development milestone nx advanced oncology product candidate sell osi milestone payment receive osi recognize contract revenue receipt base december net book value oncology asset sell million transaction cost million million relate acceleration approximately option purchase gilead common stock realize pretax gain million fourth quarter carry value transfer asset relate primarily certain property equipment osi assume gilead oncologyrelate clinical preclinical obligation lease obligation relate manufacturing agreement produce osi liposomal formulation nx gs l liposomal product sell osi manufacturing facility san dimas sale marketable security july gilead sell remain share osi common stock approximately million share partial consideration sale oncology asset osi december time record fair market value approximately million connection sale remain share recognize nonoperate loss approximately million reflect result year end december availableforsale security follow summary availableforsale security estimate fair value availableforsale security base price obtain commercial pricing service thousand gross gross amortize unrealize unrealized estimate cost gain loss fair value december treasury security obligation government agency corporate debt security assetbacke security debt security total december treasury security obligation government agency certificate deposit corporate debt security corporate equity security assetbacke security debt security total debt security consist primarily money market fund maintain marketable security nominal value record noncurrent asset december security net unrealize loss approximately million follow table present certain information relate sale availableforsale security thousand year end december proceed sale gross realize gain sale gross realize loss sale december million portfolio marketable security exclude million assetbacked security contractual maturity year million portfolio contractual maturity great year year estimate maturity assetbacked security exceed year note receivable december arrangement contemplate propose acquisition triangle gilead million loan extend triangle work capital corporate purpose triangle issue gilead unsecured convertible promissory note completion triangle acquisition january loan eliminate consolidated result result closing acquisition january note balance sheet detail thousand december inventory raw material work process finish good total property plant equipment net building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment capitalize lease equipment construction progress accumulate depreciation amortization total accrue liability accrue medicaid rebate accrue sale marketing expense liability total collaborative arrangement contract glaxosmithkline april gilead gsk enter licensing agreement provide gsk right commercialize hepsera gilead antiviral treatment chronic hepatitis b asia latin america certain territory agreement gilead retain right hepsera united states canada eastern western europe australia new zealand gsk receive exclusive right develop hepsera solely treatment hepatitis b territory significant include china korea japan taiwan addition gsk pay upfront licensing fee million entitle receive additional cash payment million achievement gsk certain regulatory development commercial milestone million million receive approval hepsera september gsk pay gilead royalty net sale hepsera gsk territory gsk responsibility development commercialization hepsera gsk territory million upfront fee million approval fee record defer revenue total million recognize contract revenue balance defer revenue december amortize contract revenue period gilead remain obligation agreement approximately year december gilead enter agreement glaxo wellcome gsk give gilead right gs l novel antitumor compound gilead develop gs l liposome evaluate preclinical study agreement gilead exclusive worldwide right develop commercialize gs l indication malaria gilead pay gsk upfront fee include rd expense december compound assign osi sale oncology asset gilead enter threepart collaboration gsk gsk receive nonexclusive right use gilead proprietary selex process target validation b gilead receive exclusive right subject gsk right elect participate activity develop commercialize nx liposomal formulation gsk proprietary topoisomerase inhibitor lurtotecan c gsk acquire share gilead common stock million private offering december collaboration license agreement modify revise term agreement gsk waive right participate development commercialization nx right receive royalty give gilead exclusive right compound december compound assign osi sale oncology asset cubist pharmaceutical september gilead cubist pharmaceutical jointly announce termination licensing agreement commercialization cidecin daptomycin injection oral formulation daptomycin agreement execute january grant gilead exclusive commercialization right product european country follow regulatory approval term termination agreement gilead owe future payment cubist cubist reacquire european right product termination million record research development expense represent remain unamortized asset relate preclinical oral formulation daptomycin archemixin october enter agreement archemix corporation relate selex technology agreement archemix obtain exclusive right selex process include therapeutic commercial application extent license preexist agreement archemix pay million million require license agreement university license equity holdings inc ulehi pay million million payment ulehi recognize million million revenue respectively receive warrant purchase share archemix common stock value material require license agreement ulehi transfer warrant ulehi additional payment archemix agreement eyetech march gilead enter agreement eyetech pharmaceuticals inc relate proprietary aptamer eye know macugen currently early clinical trial macugen inhibitor vascular endothelial growth factor vegf know play role development certain ophthalmic disease term agreement eyetech receive worldwide right therapeutic use macugen product successfully commercialize eyetech pay royalty worldwide sale product eyetech responsible research development cost provide clinical supply product eyetech march receive million upfront licensing fee eyetech april recognize revenue ratably oneyear supply agreement period accordingly million license fee record contract revenue agreement remainder license fee recognize revenue entitle additional cash payment eyetech million eyetech reach certain macugen development milestone additionally receive warrant purchase share eyetech series b convertible prefer stock exercisable price share price stock issue investor note description account treatment warrant fujisawa right market ambisome subject agreement gilead fujisawa healthcare inc successor fujisawa usa inc fujisawa term fujisawa agreement amend fujisawa gilead copromote ambisome fujisawa sole marketing right ambisome canada exclusive marketing right ambisome rest world provide pay royalty fujisawa connection sale significant asian market include japan connection sales fujisawa purchase ambisome gilead cost sale canada fujisawa purchase ambisome cost plus specify percentage fujisawa collect payment sale ambisome canada receive fujisawa gross profit sale ambisome gross profit include deduction cost good sell give current effective royalty rate approximately fujisawa net sale ambisome connection agreement fujisawa record royalty revenue million million million sumitomo september gilead sumitomo enter agreement pursuant sumitomo agree develop market ambisome japan term agreement sumitomo pay initial million licensing fee withholding taxis million october million milestone payment withholding taxis million march sumitomo require additional payment certain clinical commercial milestone meet pay royalty japanese ambisome sale agreement gilead obligate provide certain quantity ambisome sumitomo charge ambisome approve marketing japan subsequent cumulative effect change accounting principle record effective quarter result adoption sab gilead recognize initial license fee remain free supply arrangement period net impact change accounting principle sumitomo license increase net loss million cumulative effect change accounting principle charge million contract revenue million relate initial licensing fee sumitomo recognize contract revenue million recognize contract revenue remain million recognize contract revenue roche september gilead enter collaboration agreement roche develop commercialize therapy treat prevent viral influenza roche agreement roche agreement roche receive exclusive worldwide right gilead proprietary influenza neuraminidase inhibitor prior roche license fee developmental milestone payment total million gilead recognize million contract revenue milestone payment roche relate tamiflu milestone achieve year milestone include file regulatory approval japan treatment influenza japanese approval application file regulatory approval prevention influenza receipt approval recognize million milestone payment filing application market tamiflu prophylaxis european union recognize million milestone payment european approval tamiflu treatment prophylaxis december gilead entitle additional cash payment roche million roche achieve additional developmental regulatory milestone addition roche require pay gilead royalty net product sale gilead begin receive royalty roche sale tamiflu quarter record total million tamiflu royalty million royalty million royalty recognize royalty revenue roche quarter follow quarter relate tamiflu sale occur roche agreement roche reimburse relate rd cost program funding cost quarterly generally advance base annual budget reimbursement include contract revenue incur relate rd cost amount incur excess amount fund reimburse subject roche approval event revenue recognize approval obtain conversely amount fund roche exceed relate rd cost require repay excess funding roche record contract revenue rd reimbursement relate roche agreement approximately million previous year end rd costsrelate roche agreement approximate reimbursement revenue include rd expense pharmacia august gilead pharmacia corporation pharmacia enter license supply agreement pharmacia agreement market vistide country outside term pharmacia agreement pharmacia pay gilead initial license fee million subsequent cumulative effect change accounting principle record effective quarter gilead recognize initial license fee straightline basis supply arrangement period sixteen year agreement date net impact change accounting principle pharmacia agreement increase net loss million cumulative effect change accounting principle relate initial license fee pharmacia million charge result operation additional contract revenue million recognize subsequent accounting change remain million relate deferred revenue expect recognize straightline basis contract revenue remain supply period term pharmacia agreement relate agreement cover expand access program vistide outside gilead responsible maintain cidofovir patent portfolio supply pharmacia bulk cidofovir manufacture finish vistide product gilead entitle receive royalty base pharmacia sale vistide gilead receive portion royalty ship bulk drug substance vistide pharmacia remainder pharmacia sale vistide party royalty gilead receive product sell party record defer revenue thirdparty sale occur december record balance sheet approximately million defer revenue million december recognize royalty revenue sale vistide outside united states pharmacia million million million somalogic november gilead somalogic inc somalogic enter agreement gilead assign somalogic sole exclusive license certain intellectual property relate selex process diagnostic purpose include patent patent application term agreement somalogic require pay gilead total million nonrefundable installment million pay november include contract revenue year end december remain million report defer revenue december receive record contract revenue gilead ongoing research funding obligation agreement iocbrega gilead enter agreement institute organic chemistry biochemistry academy sciences czech republic rega stichte iocbrega relate certain nucleotide compound discover institution agreement gilead receive exclusive right manufacture use sell nucleotide compound gilead obligate pay iocbrega percentage net revenue receive sale product contain compound subject minimum royalty payment product cover agreement include vistide hepsera viread exclude tamiflu gilead currently make quarterly payment iocbrega base percentage vistide hepsera viread sale december agreement iocbrega amend provide reduce royalty rate future sale hepsera viread return payment gilead million signing agreement payment record longterm prepay royalty classified noncurrent asset balance sheet december recognize royalty expense expect commercial life viread hepsera amortization million payment begin product launch date viread hepsera total million december southern research institute december gilead enter agreement southern research institute give gilead worldwide right develop commercialize gs antitumor compound gilead evaluate preclinical study term agreement gilead pay southern research institute upfront fee include research development expense december compound assign osi sale oncology asset investment sale unconsolidated affiliate july establish proligo llc delaware limited liability company proligo wholly own subsidiary transfer asset nexstar technology product division proligo proligo supply nucleic acid peptide synthesis product pharmaceutical biopharmaceutical industry sale use laboratory research reagent therapeutic diagnostic product august sell interest interest proligo skw americas inc skw payment interest receive million cash interest perseptive biosystem gmbh company hamburg germany hamburg company specialize manufacture nucleoside phosphoramidite monomer interest hamburg company fair market value approximately million record million gain connection sale january october gilead additional cash investment proligo total million maintain ownership interest proligo gilead commitment provide additional funding proligo january account investment proligo equity method accounting recognize million equity proligo net loss represent share proligo loss thirteenmonth period end december fourth quarter proligo change fiscal year end december november gilead sell interest proligo degussa corporation million cash proceed net gilead investment proligo reflect million gain sale unconsolidated affiliate prior date sale gilead record million equity loss proligo longterm obligation longterm obligation consist follow thousandsdecember capital lease obligation monthly installment interest rate range fix rate debt monthly installment secure equipment interest rate range total longterm obligation current portion longterm obligation year maturitie longterm obligation include capital lease obligation follow thousand year end december represent interest total term debt agreement require comply certain financial operating covenant december compliance covenant convertible note december gilead issue million convertible senior note december private offer goldman sachs co resold note qualified institutional investor note convertible total share gilead common stock share conversion price high gilead common stock price note issuance date note redeemable option gilead time june specify redemption price plus accrued interest debt issuance cost million incur connection issuance note record noncurrent asset amortize interest expense straightline basis contractual term note december gilead issue million convertible subordinated note december private offering jp morgan co lehman brothers morgan stanley dean witter resold note private institutional investor note convertible total share gilead common stock share conversion price high gilead common stock price note issuance date note redeemable option gilead time december specify redemption price plus accrued interest debt issuance cost million incur connection issuance note record noncurrent asset amortize interest expense straightline basis contractual term note commitment contingency lease arrangement enter longterm noncancelable operating lease equipment facility facility lease foster city san dimas california expire date lease fiveyear renewal option exception lease foster city expire contain renewal option operate lease sale marketing administrative facility europe australia term equipment lease include corporate airplane initial term year annual renewal option year lease expense net sublease income operating lease total approximately million million million addition assume facility lease durham north carolina connection acquisition triangle january lease approximately square foot administrative office laboratory space sublease approximately square foot party lease expire september currently negotiation lessor extend lease term aggregate noncancelable future minimum rental payment operate capital lease net aggregate future minimum rental receive noncancelable sublease follow thousandsoperating lease net noncancelable sublease exclude triangle lease year end december capital lease represent interest total capital lease obligation current portion capital lease obligation year december placed million bank escrow deposit include noncurrent asset secure aggregate future payment facility lease contingent liability gilead sublease certain facility primarily california sublessee default obligation sublease primarily liable original lessor total future amount lease december million legal proceeding reach settlement elan corporation plc elan successor company liposome company company agree dismiss legal proceeding involve ambisome gilead liposomal formulation amphotericin b term initial settlement agreement initial payment elan million agree additional royalty payment base ambisome sale record million accounting charge accrue litigation settlement expense represent estimate net present value future minimum payment require june elan gilead enter agreement terminate remain ambisome payment obligation initial settlement agreement exchange payment elan million excess million settlement remain accrue litigation settlement expense balance million amortize remain life patent approximately year november ulehi notify ulehi believe gilead materially breach licensing agreement ulehi concern selex technology identify aptamer thing assign right agreement ulehi consent contest ulehi allegation meet ulehi allegation actively engage negotiation settle disagreement negotiation prove unsuccessful ulehi choose terminate ulehigilead agreement arbitration concern termination likely result unfavorable outcome arbitration rise award monetary damage adverse remedy possibly include conveyance ulehi gilead right obligation ulehi licensing agreement sublicense party legal action arise ordinary course business believe legal action material adverse impact business result operation financial position stockholder equity prefer stock gilead share authorize preferred stock issuable series board directors board authorize determine designation power preference right series reserve share prefer stock potential issuance preferred share purchase right plan prefer stock outstanding december employee stock purchase plan gilead employee stock purchase plan espp employee purchase share gilead common stock base percentage compensation purchase price share equal low percent market value date offer date purchase total share common stock reserve issuance espp december share total share reserve issue espp share december stock option plan december gilead adopt incentive stock option plan supplemental stock option plan issuance common stock employee consultant scientific advisor april board approve grant certain additional nonqualified stock option term condition substantially similar grant supplemental stock option plan option issue plan describe exercise price fair value underlie stock date grant option vest year pursuant formula determine board expire year share available grant future option plan november gilead adopt stock option plan plan issuance common stock employee consultant option issue plan shall discretion board incentive stock option nonqualifie stock option plan amend exercise price stock option equal fair value gilead common stock date grant option vest year pursuant formula determine board expire year plan amend restate april extend term plan stockholder approve amendment plan increase total number authorize share plan december share available grant future option plan november gilead adopt nonemployee director stock option plan director plan issuance common stock nonemployee directors pursuant predetermine formula exercise price option grant director plan equal fair value gilead common stock date grant option vest year date grant quarterly percent installment expire year stockholder approve amendment director plan increase total number authorize share plan december share available grant future option director plan stock plan assume gilead merger nexstar include stock option plan plan incentive stock plan director option plan collectively nexstar plan option pursuant plan incentive stock plan issue outstanding july convert option purchase gilead common stock result merger remain subject original term condition share available grant future option nexstar plan nexstar plan allow certain option holder execute cashless exercise option cashless exercise transaction option holder specify share exercise gilead issue specify number share number require cover exercise price base fair value stock exercise date option holder perform cashless exercise result option award consider variable recognize nominal compensation expense million million july option outstanding category follow table summarize activity gilead nexstar stock option plan year period end december option grant present table exercise price fair value underlie stock grant date share thousand year end december weight weight weight average average average exercise exercise exercise share price share price share price outstanding beginning year grant forfeit exercise outstanding end year exercisable end year weight average fair value option grant follow summary gilead option outstanding option exercisable december option thousand option outstanding option exercisable weighted average weight remain average weighted option contractual exercise option average range exercise price outstanding life year price exercisable exercise price total company reserve aggregate share common stock future issuance equity compensation plan december pro forma disclosure elect follow accounting principle board opinion apb account employee stock option apb compensation expense recognize exercise price employee stock option equal market price underlie stock date grant information net income loss earning loss share prepare accordance fas determined account employee stock option employee stock purchase plan fair value method prescribe fas earning loss share method fas result effect net income loss earning loss share pursuant fas likely representative effect net income loss earning loss share pursuant fas future year subsequent year include additional grant year vest table present combine net income loss basic diluted net income loss common share compensation cost gilead nexstar stock option plan espp determine base estimate fair value award plan grant purchase date thousand share amount year end december net income lossa report deduct total stockbase employee compensation expense determine fair value base method award net relate tax effect pro forma net income loss earning loss share basica report basicpro forma diluteda report dilutedpro forma fair value award grant stock option plan espp estimate grant purchase date blackschole option pricing model multiple option approach follow assumption year end december expect life year vest date stock option espp discount rate stock option espp volatility expect dividend yield weight average estimate fair value espp share purchase preferred share purchase right plan november adopt preferred share purchase right plan plan provide distribution prefer stock purchase right dividend share gilead common stock purchase right currently exercisable certain condition involve acquisition propose acquisition person group common stock purchase right permit holder holder purchase gilead common stock discount market price time payment specify exercise price purchase right addition event certain business combination purchase right permit purchase common stock acquirer discount market price time certain condition purchase right redeemed board price purchase right purchase right voting privilege attach automatically trade gilead common stock october board director approve amendment purchase right plan amendment provide thing increase exercise price right plan extension term plan november october acceleration stock option december complete sale oncology asset osi transaction accelerate approximately option purchase gilead common stock value million note discussion comprehensive income loss follow reclassification adjustment require avoid doublecounte net realize gain loss sale security previously include comprehensive income prior sale security thousand year end december net gain loss sale security comprehensive income net unrealize gain loss arise year reclassification adjustment net unrealized gain loss report comprehensive income loss balance accumulate comprehensive income report balance sheet consist follow component thousand december net unrealized gain availableforsale security net unrealize gain cash flow hedge net foreign currency translation loss accumulate comprehensive income disclosure segment enterprise related information gilead determine reportable segment management organize business functional line product sale consist follow thousands year end december viread ambisome follow table summarize revenue external customer collaborative partner geographic region revenue attribute country base location customer collaborative partner thousand year end december united states united kingdom france spain germany italy switzerland european country country consolidate total revenue december net book value property plant equipment million approximately asset locate december net book value property plant equipment million approximately asset locate product sale distributor account approximately total revenue product sale distributor exceed total revenue product sale distributor account approximately total revenue total revenues fujisawa include product sale royalty approximately total revenue revenue roche include royalty milestone payment reimbursement research development expense exceed total revenue account approximately total revenue income taxis gilead defer provision income taxis current provision income taxis consist follow thousands year end december current provision federal state foreign foreign pretax loss million million million difference provision taxis income compute apply federal statutory income tax rate income provision income taxis equity loss unconsolidated affiliate cumulative effect change accounting principle explain thousands year end december income loss provision income taxis equity loss unconsolidated affiliate cumulative effect change accounting principle tax federal statutory rate benefit unbenefitted loss federal alternative minimum taxis december federal net operating loss carryforward million state net operating loss carryforward million federal net operating loss carryforward expire date begin utilize state net operating loss carryforward expire date utilize addition federal state tax credit carryforward approximately million million respectively expire year utilization net operating loss credit subject annual limitation ownership change limitation provide internal revenue code similar state provision annual limitation result expiration net operating loss credit utilization significant increase income tax expense result principally gain sale oncology asset osi record approximately million federal state alternative minimum taxis provision reduce change income tax law law allow net operating loss carryforward deduction offset alternative minimum taxable income result reduction income tax record previous year million defer income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component defer tax asset liability december follow thousand december net operating loss carryforward research credit capitalize research development expense reserve accrual currently deductible net total defer tax asset valuation allowance net defer tax asset recognize valuation allowance increase million year end december decrease million year end december approximately million valuation allowance december relate tax benefit stock option deduction credit additional paidin capital realize retirement saving planas december gilead maintain retirement saving plan eligible employee defer compensation income tax purpose section k internal revenue code prior january gilead maintain separate retirement saving plan plan primarily cover nexstar employee nexstar plan plan primarily cover gilead remain eligible employee gilead plan nexstar plan employee contribution exceed eligible annual compensation addition nexstar plan include company match employee contribution maximum contribution annual maximum company match december approximately million represent share gilead common stock hold nexstar plan trust plan participant effective january nexstar plan terminate combined gilead plan share gilead common stock hold nexstar plan subsequently liquidate proceed deposit investment option available gilead plan gilead plan employee contribute eligible annual compensation effective january gilead begin make match contribution gilead plan contribute employee contribution annual maximum match total matching contribution gilead plan million million combine million plan relate party transaction december chairman gilead board director senior advisor investment fund own control interest pharmaresearch corporation contract research organization perform service connection clinical study gilead payment pharmaresearch corporation million december arrangement contemplate propose acquisition triangle pharmaceuticals inc gilead million loan extend triangle work capital corporate purpose triangle issue gilead unsecured convertible promissory note completion triangle acquisition january loan eliminate consolidated result result closing acquisition january note subsequent event january complete acquisition outstanding stock triangle development stage company triangle active development antiviral drug candidate aggregate preliminary purchase price million include cash pay outstanding stock fair value option assume estimate direct transaction cost employee termination cost intend account transaction quarter expect record substantial portion aggregate purchase price inprocess research development expense quarterly result unaudite follow table thousand share amount st quarter nd quarter rd quarter th quarter total revenue total cost expense net income loss net income loss common sharebasic net income loss common sharedilute st quarter nd quarter rd quarter th quarter total revenue total cost expense income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amount common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharebasic amount common sharedilute income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharedilute year end december gilead adopt sfas report cumulative effect change accounting principle quarter dilute net income common share fourth quarter include effect stock option million convertible subordinate note december complete sale oncology asset osi record nonoperating gain million fourth quarter result transaction gilead sciences inc schedule ii valuation qualifying account addition balance balance begin charge charge end period expense deduction period year end december allowance doubtful account allowance sale return valuation allowance defer tax asset year end december allowance doubtful account allowance sale return valuation allowance defer tax asset year end december allowance doubtful account allowance sale return valuation allowance defer tax asset charge current tax expense charge defer tax benefit